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microRNAs (miRNAs) are small non-coding RNA which play an important role in gene
regulation. Majority of miRNAs are encapsulated in exosomes thereby confer protection
against degradation and transport across cell. Recent study suggests that 1) humans
absorb microRNAs from cow’s milk, 2) milk microRNAs are delivered to peripheral
tissues where they alter the expression of human genes, and 3) endogenous synthesis of
microRNAs does not compensate for dietary microRNA depletion in mice. Studies
suggest that cow’s milk exosomes can be transported across the intestinal mucosa by
processes involving endocytosis and exocytosis. Here we tested the hypothesis that
endothelial cells also transport milk exosomes. Using FM-labelled exosomes, the
transport of exosomes in HUVECs can be assessed, i.e., the quantitatively most important
fraction of exosomes in milk taken up by HUVECs. Exosome uptake followed MichaelisMenten kinetics (Vmax = 0.057±0.004 ng exosome protein x 40,000 cells-1 x hour-1; Km=
17.97±3.84 µg protein/200 µl media) and decreased by 80% when the incubation
temperature was lowered from 37°C to 4°C, consistent with carrier-mediated transport.
When exosome surface proteins were removed by treatment with proteinase K or
transport measured in the presence of carbohydrate competitors, transport rates decreased
by 30% to 50% compared with controls, consistent with a role of surface glycoproteins in

endothelial transport. Treatment with cytochalasin D caused a 50% decrease in transport,
consistent with endocytosis. We conclude that human endothelial cells transport bovine
exosomes by endocytosis and propose that this is an important step in the delivery of
exosome cargo to peripheral tissues.
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Chapter 1
Literature Review

2

Extracellular Vesicles (EVs)
Extracellular vesicles (EVs) are term used to describe the diverse types of plasma
membrane or endosomal vesicle origin (1). They appears in spherical form and composed
by phospholipids and specific proteins which separates them from plasma membrane
origin with size ranging from 30 nm to 1 µm (2-4). They are secreted by both eukaryotic
and prokaryotic cell into the environment for cell-to-cell communication, protection, and
exchange of genetic information (5).
In the beginning, EVs were considered as cellular debris, which is resulted from
the membrane remodeling of apoptotic cells (6). Indeed, the first and well-known EVs
was apoptotic bodies which is released during apoptosis. However, healthy cells also
release vesicles which comprised by large and small vesicles (7-10). Some EVs are
derived from the shedding of plasma membrane which latter known as shedding vesicles
or microvesicles (11), whereas other EVs are derived from the exocytosis process of
multivesicular bodies (MVB) which known as exosome (12). These two types of EVs are
majorly found to be released by the cell into the plasma as well in other biological fluids
such as semen, saliva, urine, breast milk, cerebrospinal fluids, bronchoalveolar and
lavage fluid, amniotic fluid, and malignant ascites (13-18).
Perhaps the first experiment regarding the presence of EVs was dated back in
1967 when Wolf (19) reported phospholipids rich small vesicle ranging from 20 to 50 nm
from the platelet termed “platelet dust” that contains the platelet factor 3 for blood
coagulation. Ultracentrifugation removed the small vesicle and caused a prolonged blood
coagulation. The presence of small vesicles were confirmed later in fetal bovine serum,
nerve tissue, healthy cell and cancerous cell with unknown biological function (7-9). In
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the early 1980s, two independent researchers have identified the function of this small
vesicle for transporting transferrin and its receptor during reticulocyte maturation (10,
20). Further electron microscopy identified that the small vesicle was formed by inward
budding of plasma membrane into intracellular endosomes followed by exocytosis of late
endosome or multivesicular endosomes (MVBs) (10, 21). Term “exosomes” than had
been used to characterize this small vesicles produced by mature reticulocytes which
carry the transferrin receptor without the presence of cytosolic enzyme that can be
isolated using centrifugation technique (12, 22). Noted that the term exosome used here
should be distinguished from the RNA degrading complex in the cytosol (23).
However, these findings were not appreciated enough until Raposo et al. (24)
reporting the presence of major histocompatibility complex (MHC) class II in exosomelike vesicle produced by antigen presenting cell. This result indicated that exosome is not
only produced by the reticulocytes, but also from other cells such as B cell. This finding
was confirmed by several studies that cancer and other normal cells also produce
exosome vesicle that carry functional enzyme (25), mRNA (26) and microRNA (27, 28).
Since then, large body of articles have identified numerous EVs isolated from different
cell with distinct functional therapies such as cardioprotection (29), drug delivery (30),
stroke therapy (31), and gene therapy (32).
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Classification of Cell Derived EVs
Although several cell derived EVs have been well characterized in numerous
studies, however there is no consensus regarding the nomenclature and characteristic of
cell derived EVs (33, 34). This condition led to the confusion on determining the cell
derived EVs. For instance, one can use the term “ectosomes” (35, 36), “exosome-like
vesicles” (37, 38), “argosomes” (39), “tolerasomes” (40, 41), “prostasomes” (42),
“cardiosomes” (43) or “vexosomes” (44) to explain small vesicle with size <100 nm. The
term of microparticles and microvesicles have been used collectively by numerous
authors to describe direct, vesicular form of membrane shed vesicles with size >100 nm
(45). Moreover, exosomes can be defined in different ways, i.e., the exfoliated plasma
membrane, which has the plasma ecto-enzyme activity (9), or the vesicles that formed by
inward budding of limited plasma membrane into endosome to form MVBs followed by
exocytosis process of MVBs after fusion with plasma membrane (22). In order to make
the classification clear, the term microvesicles (MVs) will be used instead of
microparticle to explain vesicle larger than 100 nm.
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Table 1.1. Characteristics of different types of cell derived EVs*)
Feature

Exosome

Microvesicles

Membrane

Ectosomes

Particles
Size (nm)
Density

Exosome-like

Apopto-

particle

tic bodies

30-100

100-1,000

50-80

50-200

20-200

50-5000

1.13-1.19

ND

1.03-1.07

ND

1.12-1.18

1.16-1.28

(g/ml)
Mechanism

Exocy-

Budding/blebbing

Budding/

Budding/

ND

Release

of

tosis of

of plasma

blebbing of

blebbing of

from

generation

MVBs

membrane

plasma

plasma

dying/ap

membrane

membrane

optotic
cells

Morphology

Cup-

Irregular shape

Round

shaped
Origin

Endoso-

Bilaminar

Cup-shaped

round
Plasma membrane

mes

Heteroge
neous

Plasma

Plasma

Internal

membrane

membrane

compartment

ND

?
Protein

Tetra-

Annexin V,

CD133

markers

spanin

integrins,

CR1-

(CD63,

selectins, CD40

related

CD9,

ligands

enzyme

CD81),
LAMP,
Alix,
TSG101

*) Adapted from (13, 35, 45-50). ND, not defined.

CD59,

TNFRI

Histone
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Based on literature, there are several categories of cell derived EVs. Some
classified cell derived EVs into two classes (51), three classes (1, 45, 47, 49), four classes
(48) or more (46). Characteristics of cell derived EVs are reviewed in Table 1.1. These
discrepancies in classification of cell derived EVs are caused by many factors, i.e.,
isolation procedure, size, density, morphology, lipid and protein composition as well
cellular origin (33, 48). Thus, to mediate the ambiguous term in cell derived EVs
research, International Society of Extracellular Vesicles (ISEV) has proposed some
criteria to represent the minimal characterization of EVs. These including: 1) the
presence or absence of some protein marker, which can be detected by western blot, flow
cytometry, or mass-spectrophotometry, 2) characterization of single vesicles should be
performed by using electron microscopy in wide area accompanied by size distribution
measurement, 3) presence of controls in the studies of the functional activity of EVs (34).
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Exosome
Exosome is small, nano-sized vesicle with diameter of 30-100 nm and density of
1.13-1.19 g/mL (50). It is secreted by normal or cancerous cell in spontaneous or
inducible processes (9, 52, 53). It is present in biological fluid such as plasma, saliva,
urine, breast milk, bronchoalveolar lavage fluid, amniotic fluid, cerebrospinal fluid, and
malignant ascites (13, 14, 17, 54).
Exosome term was first determined by Trams et al (9) as a vesicle derived from
the plasma membrane although the term was started to change two years afterwards when
two independent researchers, Harding et al (10) and Pan et al (20), discovered a small
vesicle formed from inward budding of late endosomes. This small vesicle contains
transferrin receptor, which add another route for transferrin receptor recycle during
maturation of red blood cells (12). Electron microscopy further revealed the formation of
intraluminal vesicles (ILV) formed by invagination or budding from limited membrane of
endosome, which will fuse with plasma membrane to release small vesicle through
exocytosis process (10, 21). Small vesicles, which are released from MVBs, were later
termed “exosome” (22) and later were confirmed in B-cell by Raposo et al (24). Since
then, term exosomes is used to describe the small vesicles formed by the inward budding
of endosomes (Figure 1).
Exosomes harbor protein, lipid, carbohydrate and nucleic acids such as miRNA,
small non-coding RNA and mRNA which derived from their cellular origin (55). These
components, particularly miRNA, reflect the functionality to the host cell and posse
molecular signature from their cellular origin (38, 47, 56-58). Therefore, it was thought
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that molecular characterization of exosome exert potential biomarker of the disease such
as cancer.
The protein content in exosome comprised by protein involved in MVBs
generation such as membrane transport and fusion protein (e.g., Rab, annexins, flotillins),
MVB biogenesis (e.g., ESCRT family: Alix, TSG101), cytoskeletal protein (e.g., actin,
tubulin, syntenin, and moesin) and tetraspanin (e.g., CD63, CD9, CD81, CD82) although
other proteins which is not related to the MVBs generation also present in exosome such
as metabolic enzymes, heat shock protein, ubiquitin, and protein important for signal
transduction, apoptosis and protein synthesis (46, 59, 60). Protein contents in exosomes
are reviewed in Table 1.2.
The lipids of exosome comprised by cholesterol, phospholipids, sphingolipids,
ceramides and lipid raft molecule (1, 46, 47). The carbohydrates in exosome is enriched
in mannose, polylactosamine, α-2,6 sialic acid and complex N-glycans, which is
important for protein recruitment in exosome (61-63). All of these components discrete
exosomes from other organelle or plasma membrane (47). Currently, all of the protein
and lipid components of exosomes are available online from three databases; EVpedia,
Exocarta and Vesiclepedia (64, 65).
Exosome also carry nucleic acids which can be translated into functional protein
or regulate the activity of gene (26, 66, 67). Several RNA families such as messenger
RNA (mRNA), microRNA (miRNA), transfer RNA (tRNA), ribosomal RNA (rRNA),
piwi RNA (piRNAs), mitochondrial RNA (mitRNA) and long non-coding RNA present
in exosome (60, 68-70). The presence of nucleic acids, especially the miRNA, are
thought to be a reliable marker for exosome due to the equal level of miRNA in exosome
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compared with the parental cell (15, 70, 71). However, identification of miRNA in
exosome is challenged due to the low level of miRNAs in exosome compared to their cell
origin (72). In addition, recent studies also suggest that other proteins; e.g., the HDL and
argonaute, also transport miRNA which limit the potential use of miRNA detection as a
marker of exosome (73-75).
Based on the first discovery of exosomes, the exocytosis process of MVBs is the
general process of exosomes biogenesis. The engulfment of plasma membrane by clathrin
or non-clathrin coated pits resulting in early endosome was the first pathway in exosome
biogenesis. The formation of early endosome was followed by multivesicular bodies
(MVBs) development through trans-golgi network protein interaction, i.e., endosome
sorting complex required for transport (ESCRT), resulting in the formation of
intraluminal vesicle (ILV). The ESCRT protein family is also important for the fate of
MVBs (76). The fusion of MVBs with the plasma membrane resulted in the releasing of
exosomes. This mechanism is first confirmed in red blood cell, which was also
established in dendritic cells (77).
However, there are other exosome biogenesis pathways, which are ESCRTindependent process. This pathway rises as silencing the production and activity of
TSG101 or ESCRT complex did not hamper the production of exosome in some type of
cells (53, 78, 79). For instance, silencing the production of CD69 protein in melanocyte
has caused significant reduction in exosome biogenesis (80) while inhibiting ceramide
production in oligodendroglial cell has resulted in lower production of exosomes (81).
These results indicated the ESCRT-independent pathway for exosome biogenesis as well
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the cellular specific pathway for exosome biogenesis, which may explain the variety on
molecular signature in exosomes (82).
Upon releasing into the plasma or serum, recent direct and indirect evidence
reported that exosomes are taken up by the cell through several proposed mechanisms in
order to transfer the cargo into recipient cells. Studies showed that exosomes uptake is
endocytosis-dependent process as indicated by fluorescence microscopy method (83-88).
In addition, other types of endocytosis process, i.e., phagocytosis and micropinocytosis,
have been reported (89, 90). However, exosomes are also transported by direct fusion
with plasma membrane of the cell, which suggesting the endocytosis-independent
pathway for cellular internalization of exosomes (91).

Microvesicles
Microvesicles, also known as shedding vesicles, microparticles, ectosomes or
membrane particles, is vesicles produced by outward budding and fission of plasma
membrane (51, 92). They are found in most of biological fluids as well in atherosclerotic
plaque (93, 94). Unlike exosomes, this small vesicles has heterogeneous shape, larger in
diameter (from 100 nm up to 1 µm) and float in sucrose gradient with density of 1.0321.07 g/mL, slightly lower than exosomes (46, 48, 92).
Microvesicles were first characterized by Wolf (19) as “platelet dust” that contain
platelet factor 3 for blood coagulation. The vesicles were comprised by phospholipid rich
vesicles and secreted by most type of cells in the body including circulating cells,
vascular cells, and cardiomyocytes (95). Stress, hypoxia, apoptosis, inflammation,
complement attack, bacteria lipopolysaccharides (LPS), intercellular calcium elevation,
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senescence and platelets activation have been reported to stimulate the release of
microvesicles (96-102). Thus, microvesicles play important role in coagulation (103),
atherosclerosis development (104), tumor invasion and metastases (94), immunity and
inflammatory modulator (105-107).
Due to the plasma membrane origin, microvesicles contain several proteins and
lipid from plasma membrane origin. In addition, microvesicles also acquired some
protein from plasma or endocytic compartment, which indicated sorting protein process
in microvesicles (99, 110). Although, they are originated from plasma membrane of the
cells, protein and lipid component of microvesicles, as well the cargo content of
microvesicles, are depend on several factors; i.e., cellular origin, cellular stage (e.g.,
resting, stimulated), and the stimulation agent (111). For instance, stimulation of platelet
with complement complex C5b-9 resulted in platelet-derived microvesicles enriched in
C9 neoantigen of the C5b-9 complex and α-granule-derived-coagulation factor V (or Va)
(112). In addition, stimulation with this agent produced platelet-derived microvesicles
that did not bind with fibrinogen (113).
Although it is cleared that microvesicles was originated from plasma membrane
of the cells, formation and released of microvesicles from plasma membrane is poorly
understood. It is hypothesized that activated cells will cause an elevation of calcium level
in the cytosol, particularly in site of vesiculation, will cause activation of kinases and
calpain as well inhibition of phosphatases, which in turn will break the membrane
cytoskeleton, releasing microparticles to extracellular compartment of the cells (98). Prior
to membrane breakdown, it is hypothesized that non-secretory exocytic vesicles will
accumulate into the plasma membrane, causing the budding of plasma membrane (51).
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This event is characterized by the presence of desmoyokin and annexin 2, a marker of
exocytic organelle, in microvesicles (111). It is also reported that budding of
microvesicles from plasma membrane requires two important proteins: endosomal sorting
complex required for transport (ESCRT) and arrestin domain-containing protein 1mediated microvesicles (ARMMs) (114, 115). Inhibition of ARMMs along with ESCRT
inhibits the release of microvesicles from plasma membrane, which indicated the main
function of these two proteins in mediating the release of microvesicles from plasma
membrane (116).
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Figure 1.1. Formation of exosome from multivesicular endosome. A limited plasma
membrane is engulfed into the early endosome where it will mature into multivesicular
endosome with the formation of intraluminal vesicle (ILV) derived from late endosome.
The multivesicular endosome then fused with the plasma membrane to release small
vesicle containing transferrin receptor. Adapted from Thery et al (46).

14

Table 1.2. Protein and glycolipid content of exosomes*)
Protein Function/Class

Protein

Antigen presentation

MHC Class I/II, CD86

Adhesion molecules/targeting

Milk Fat Globule-Epidermal growth factor VIII
(MFG-E8 or lactadherin), integrin (α3, α4, αM,
αL, β1, β2), tetraspanin (CD63, CD9. CD37,
CD53, CD81, CD82)

Membrane transport and fusion

RAP1B/RABGDI, Rab 7, Rab 2, Annexins
(Annexins 1-7), dynamin, syntaxin, AP-1,
Arp2/3, SNAP

Heat-shock protein

HSC70, HSP84/90

Cytoskeletal protein

Actin, cofilin, tubulin, moesin, rodixin, advilin,
vimentin, talin, CAP1, ezrin

Raft-associated protein or glycolipids

Flotillin, CD55, CD59, GM1, GM3, Gi2α,
cholesterol, stomatin

Enzymes

Pyruvate kinase, alpha enolase, ATPase, glucose
6-phosphate,

isomerase,

peroxiredoxin

1,

aspartate amino transferase (ASAT), fatty acid
synthetase, ATP citrate lyase
MVB formation

Alix, TSG101, Gag

Signal transduction

Erk2, Fyn, RhoA/C, catenin, syntenin

*) Adapted from (108) and (109)
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Upon the release into extracellular compartment, microvesicles are taken up by
the cells with half-life around 10 minutes in the plasma (117). Study indicated that
microvesicles are taken up by the cells through endocytosis and phagocytosis pathway
upon binding with specific receptor in the cells (118). Developmental endothelial locus
(Del)-1 is important protein that recognize the phosphatidylserine in microvesicles and
mediates the endocytosis process of microvesicles through binding with integrin, αvβ3,
on cells (119). The lactadherin, also known as milk fat globule-epidermal growth factor
8, is mediated the phagocytosis process of microvesicles upon binding with integrin of
macrophages (120). In addition, other proteins are reported to mediate the uptake of
microvesicles; growth arrest specific 6 (GAS6), β2-Glycoprotein I, P-selectin (117).

Apoptotic Bodies
Apoptosis, also known as programmed cell death, is a major mechanism of cell
death, both in cancer and normal cell, indicated by the release of membrane vesicles
called apoptotic bodies or apoptosomes (6). The apoptosis process begins by activation of
caspase protein in response to ligation of the death receptor in the cell membrane
(CD95/FAS, TNFR1, TRAILR) (121). Activated caspase will cleave certain regions of
genomic DNA, forming oligonucleosome ladder, followed by migration of
oligonucleosome into the cytosol due to increased permeability of nuclear pores (122,
123). Upon exiting the nucleus, the oligonucleosome will migrate into plasma membrane,
forming “blebs” at the plasma membrane (124, 125). It is reported that rho effector
protein I (ROCK I) is cleaved by caspase and promote the formation of apoptotic blebs
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during apoptosis (126, 127). The blebs will contain cellular organelle, which will be
cleared through phagocytosis by macrophage (128).
Although apoptotic bodies can be distinguished from others EVs; e.g., exosomes
and microvesicles, by size (500-4000 nm in diameter), study suggests the presence of
cellular organelle in small vesicles with diameter of 50-500 nm, which indicating the
apoptotic bodies (129). In addition, some proteins present in other EVs such as epithelial
cell adhesion molecules (EpCAM), CD63, CD81, which is found in most of extracellular
vesicles including apoptotic bodies, and annexin V, which is detected in microvesicles
and apoptotic bodies (130, 131). The similarity in size and protein composition between
apoptotic bodies and others EVs have added the difficulties in characterizing EVs from
the sample. Moreover, there is no established protocols for isolating apoptotic bodies.
One method that has been developed to distinguish apoptotic bodies from other EVs is
RNA analysis. Based on this technique, apoptotic bodies majorly composed by ribosomal
RNA, which is lacked in others EVs such as exosome and microvesicles (131).
Similar with other EVs, apoptotic bodies are cleared or taken up by the cells to
mediate transfer of genetic between cells. Phagocytosis by the macrophage is the major
route for apoptotic bodies’ clearance during normal development (132). The clearance
process of apoptotic bodies consisted of 4 distinct steps: accumulation of phagocytes at
the site where apoptotic cells are located through “find me” signals, recognition of
apoptotic bodies through “eat me” signals and their cognate receptors, engulfment by
macrophages through signaling pathways that regulate the cytoskeletal rearrangement of
macrophage, digestion of engulfed apoptotic bodies within macrophage (133, 134). The
presence of thrombospondin, complement protein C3b, and annexin V in apoptotic
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bodies are believed to guide the macrophage to eat the apoptotic bodies, which serve as a
protein marker for apoptotic bodies (125, 132, 133). Internalization of apoptotic bodies
into targeted cells has been reported to promote several functions such as antiinflammatory properties (135, 136), viral transfer (137), endothelial cell repair (130), as
well as cancer metastases (138).

Biological Function of Cell derived EVs
The presence of nucleic acids such as DNA, RNA, miRNA as well long non
coding RNA in EVs has risen the importance of EVs for cell-to-cell communication
(139). Indeed, the nucleic acid, particularly RNA, in EVs can be translated by recipient
cells to promote function such as transcription termination (140) and lipid synthesis
(141). Moreover, it is reported that most of detectable microRNA present in biological
fluid such as serum, saliva and breast milk is encapsulated in EVs, particularly in
exosomes (27). EVs exert potential protection against harsh environment and enzymatic
degradation (142), which contribute to the transport and genetic transfer into recipient
cells through local or systemic circulation in endocrine-like pathway (82).
Study suggest that mRNA and microRNA-containing EVs can be transmitted
across species. Using mouse dendritic cells, Valadi et al (26) have successfully
demonstrated that mRNA from mouse dendritic cells can be translated into functional
protein in human mast cells. In addition, Sun et al (143) reported the immune-related
miRNAs from cow’s milk can influence gene transcription in human macrophage cells
resulting in macrophage differentiation. Recent study conducted by our lab (67, 144) also
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supported the notion that microRNAs present in cow’s milk and egg EVs can be exported
into human blood and affect gene expression in human body.
In addition, protein, enzyme and lipid components in EVs have been proposed to
mediate several physiological or biochemical process in the body, i.e., cellular
development, differentiation, and immune function. For instance, exosomes account for
transferrin receptor transport from reticulocytes into the blood during red blood cells
maturation (10, 145). In addition, Skokos et al (146) demonstrated that exosomes
released from mast cells are able to induce maturation of immature dendritic cells (DC)
by its ability in antigen presentation to T cells. Further studies indicated that the ability of
antigen presenting of DC to T cells is mediated by exosomes released from mature DC
(147, 148).
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MicroRNA (miRNA)
microRNA (miRNAs) is small, ~21 nucleotides long, non-coding RNA that plays
an important role in gene regulation, both in animals and plants, by binding to
untranslated region of mRNA, resulting in translation inhibition or mRNA degradation
(149). It was first discovered in C. elegans as a non-coding RNA, produced by lin-4 and
let-7 genes, that binds to 3-untranslated region of lin-14, lin-28, lin-41, lin-42 and daf-12
mRNA (150, 151). Since then, let-7 RNA homolog has been identified in a wide range of
animal species, e.g., vertebrae, ascidian, hemichordate, mollusk, annelid, and arthropod
(152). This small, single stranded RNA was named miRNA and regulates as much as
60% of mammalian genes (153-156).
Since the discovery of miRNAs, other small RNAs have been characterized in
animals, plants, and fungi, which including small interfering RNAs (siRNAs) and Piwiinteracting RNAs (piRNAs) (157, 158). They have distinct characteristic, although have
similarities particularly in post-transcriptional modification. The characteristic between
miRNA, siRNA and piRNA are reviewed in Table 1.3.

MicroRNA Biogenesis, Maturation and Molecular Mechanism
Study suggest that miRNAs are encoded in the nucleus. Most of the miRNAs in
human, around two third, are encoded in the intron region of protein-coding genes as well
in long non-coding transcript (159). This condition let to the assumption that miRNAs are
transcribed along with the host genes using RNA polymerase II (160, 161). However,
Bortolin-Cavaille et al (162), reported the introgenic independent pathway of protein
coding genes for miRNAs biogenesis. They reported that miRNAs in C19MC are

20

transcribed from intron region of non-protein-coding genes. In addition, studies suggest
the role of exonic region of non-protein-coding genes for miRNA production (163, 164).
Thus, miRNA can be encoded by three genomic regions in the nucleus; 1) intronic region
of protein-coding genes, 2) exonic miRNA region in non-protein-coding genes and or 3)
intronic region of non-protein-coding genes.
Table 1.3. Characteristic of miRNA, siRNA, and piRNA*)
miRNA
Origin

siRNA

piRNA

miRNA gene (exon) Long
or

DNA

double Repetitive elements

intron stranded

(endogenous)

RNA such as retrotrans-

(endegonous and/or posons, DNA transexogenous)

posons,

and

the

Su(Stellate) locus
Configuration

Length

Single

stranded Double

stranded

RNA

RNA

RNA

19-25 nucleotides

21-22 nucleotides

21-33 nucleotides

Complementarity to Not exact
target mRNA
Action

stranded Single

100% perfect match 100%

perfect

match
Cleveage of mRNA Cleavage of mRNA Cleavage of mRNA
and/or

translation

inhibition
*)Adapted from (155, 165-168).

and recruitment of
DNA methylation
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Biogenesis of miRNAs start with the translation of genomic region of miRNA in
the nucleus. There are two enzymes: RNA polymerase II or RNA polymerase III, which
mediate the transcription of miRNA (161, 169). The resulting product are called primary
precursor of miRNA (pri-miRNA) that comprised by more than 1 kbp nucleotides with a
double stranded stem of ~33 bp, a terminal loop and two flanking unstructured singlestranded segments (160, 170). The pri-miRNA is cleaved by microprocessor complex
(nuclear RNAse III Drosha/Pasha and DGCR8) to release ~65 bp hairpin-shaped
nucleotides called precursor miRNA (pre-miRNA) (171-174). The resulting pre-miRNA
will be exported outside the nucleus using exportin-5, which require the Ran-GTP
cofactor (175, 176). In addition, the binding of pre-miRNA with exportin-5 also protects
pre-miRNA from degradation (177).
In the cytosol, pre-miRNA will subsequently cleave by another RNAse III
nuclease called dicer to produce mature, 22 nucleotides miRNAs (178, 179). Dicer will
recognize and bind to pre-miRNA in the 2-nt 3`-overhang in pre-miRNA through the
PAZ domain in dicer (180-182). The binding of pre-miRNA with dicer will create a
complex termed miRNA duplex, which will release a single stranded, mature miRNA.
The mature miRNA will form a complex with Argonaute (Ago) protein while the other
miRNA duplex will be degraded (170).
Argonaute protein and its homolog are ~100 kDa proteins, which contain both
PIWI and PAZ domain (183, 184). When the mature miRNA, as well siRNA, forms a
complex with the argonaute, the resulting complex is referred to RNA-induced silencing
complex (RISC) (185). The complex will identify the mRNA target based on the
complementary bases (perfect or nearly perfect) and cleaves the mRNA at a site near the
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middle of miRNA/siRNA complementarity (186, 187). In addition, it was proposed that
the argonaute-bound miRNA complex could repress the translation of mRNA (188, 189).
The mechanism in which miRNA-argonaute protein complex inhibits protein translation
lies in the sequence motive in argonaute protein that can bind with functional 7-methylguanine (m7G) cap of mRNA (190). Once the argonaute form a complex with m7G cap of
mRNA, this cap is not accessible for elf4E to initiate the translation process of mRNA,
resulting in translation inhibition of mRNA (191, 192).
The translation inhibition mechanism of argonaute-miRNA complex is also
postulated due to the ability in the formation of “pseudo-polysomes”, large EDTA
sensitive mRNA-protein (mRNP) assemblies (193). It is hypothesized that formation of
pseudo-polysomes was caused by protein interaction between GW182 with argonaute
protein, which causing recruitment of 80S ribosomes to mRNA (194-196). This
polysomes lack of translation machinery and reported to initiate mRNA degradation (197,
198). Biogenesis, maturation and molecular mechanism of miRNA are reviewed in
Figure 1.2.

MicroRNA in Health and Disease
Due to the important role of miRNAs in regulating gene expression in the cells,
miRNAs have been associated with health or disease progression. For instance, miR-29b
has been reported for bone remodeling through its effect in genes regulation in osteoclast
and osteoblast differentiation (199, 200) while miR-200 subfamily (miR-200b/200c/429)
has been reported to inhibit cancer metastasis in hepatocellular carcinoma (201-203).
Thus, alteration in miRNAs level may impact health and disease progression of the host
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and can potentially be used as diagnostic tools in various disease state such as carcinoma
(204, 205), osteoporosis (206), type 2 diabetes mellitus and obesity (207), as well in
cardiovascular disease (208).
Although miRNAs are considered endogenous; e.g., miRNAs synthesized by the
cells will be used by the cells to regulate the gene expression inside the cells, recent
studies suggest that dietary miRNAs may contribute to the miRNAs body pool. Indeed,
miRNAs present in food can be transferred into human through dietary means. The first
study regarding the importance of dietary miRNAs in body pool miRNAs and the effect
in human health was demonstrated by Zhang et al (210). In this study, they reported that
rice miRNA, osa-miR-168a, is detected in the mouse and human sera and inhibits mRNA
expression of LDL-receptor, thereby reducing LDL removal from the blood. However
this study was challenged by several findings regarding the low bioavailability of plant
miRNA in the blood (211-213). Interestingly, miRNAs present in milk and egg have been
reported to be absorbed in biologically meaningful amount and affect human gene
expression both in vivo and in vitro (67, 144). The discrepancies of the result was
probably caused by the encapsulation of miRNAs in EVs that protect miRNAs from
enzymatic degradation and harsh environment as well for miRNAs transportation across
species (142, 214, 215).
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Figure 1.2. Biogenesis, maturation and molecular mechanism of miRNA. In the nucleus,
miRNA is transcribed using RNA polymerase II/III to produce pri-miRNA. The primiRNA will subsequently cleave by Drosha/Pasha to produce pre-miRNA and exported to
cytoplasm using exportin/RAN-GTPAse. In the cytosol, pre-miRNA will be cleaved by
Dicer, releasing mature, single stranded miRNA. Mature miRNA will form a complex with
argonaute protein calling RNA induced-silencing complex (RISC). Several mechanisms
and possible pathways have been proposed, e.g., inhibition of translation or mRNA
degradation. Adapted from (209).

25

REFERENCES
1.

Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and
friends. The Journal of Cell Biology. 2013;200(4):373-83.

2.

Conde-Vancells J, Rodriguez-Suarez E, Embade N, Gil D, Matthiesen R, Valle M,
et al. Characterization and comprehensive proteome profiling of exosomes
secreted by hepatocytes. J Proteome Res. 2008;7(12):5157-66.

3.

Mause SF, Weber C. Microparticles: protagonists of a novel communication
network for intercellular information exchange. Circ Res. 2010;107(9):1047-57.

4.

Jayachandran M, Miller VM, Heit JA, Owen WG. Methodology for isolation,
identification and characterization of microvesicles in peripheral blood. J Immunol
Methods. 2012;375(1-2):207-14.

5.

Nieuwland R, Sturk A. Why do cells release vesicles? Thromb Res. 2010;125
Suppl 1:S49-51.

6.

Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol.
2007;35(4):495-516.

7.

Bindler E, Labella FS, Sanwal M. Isolated nerve endings (neurosecretosomes)
from the posterior pituitary. Partial separation of vasopressin and oxytocin and the
isolation of microvesicles. J Cell Biol. 1967;34(1):185-205.

8.

Dalton AJ. Microvesicles and vesicles of multivesicular bodies versus "virus-like"
particles. J Natl Cancer Inst. 1975;54(5):1137-48.

9.

Trams EG, Lauter CJ, Salem N, Jr., Heine U. Exfoliation of membrane ectoenzymes in the form of micro-vesicles. Biochim Biophys Acta. 1981;645(1):63-70.

26

10.

Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and
recycling of the transferrin receptor in rat reticulocytes. J Cell Biol.
1983;97(2):329-39.

11.

Holme PA, Solum NO, Brosstad F, Roger M, Abdelnoor M. Demonstration of
platelet-derived microvesicles in blood from patients with activated coagulation
and fibrinolysis using a filtration technique and western blotting. Thromb
Haemost. 1994;72(5):666-71.

12.

Johnstone RM, Bianchini A, Teng K. Reticulocyte maturation and exosome
release: transferrin receptor containing exosomes shows multiple plasma
membrane functions. Blood. 1989;74(5):1844-51.

13.

Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C. Exosomallike vesicles are present in human blood plasma. Int Immunol. 2005;17(7):879-87.

14.

Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: proteomic insights
and diagnostic potential. Expert Rev Proteomics. 2009;6(3):267-83.

15.

Lasser C. Exosomal RNA as biomarkers and the therapeutic potential of exosome
vectors. Expert Opin Biol Ther. 2012;12 Suppl 1:S189-97.

16.

Lasser C, O'Neil SE, Ekerljung L, Ekstrom K, Sjostrand M, Lotvall J. RNAcontaining exosomes in human nasal secretions. Am J Rhinol Allergy.
2011;25(2):89-93.

17.

Keller S, Ridinger J, Rupp AK, Janssen JW, Altevogt P. Body fluid derived
exosomes as a novel template for clinical diagnostics. J Transl Med. 2011;9:86.

18.

Madison MN, Roller RJ, Okeoma CM. Human semen contains exosomes with
potent anti-HIV-1 activity. Retrovirology. 2014;11(1):102.

27

19.

Wolf P. The nature and significance of platelet products in human plasma. Br J
Haematol. 1967;13(3):269-88.

20.

Pan BT, Blostein R, Johnstone RM. Loss of the transferrin receptor during the
maturation of sheep reticulocytes in vitro. An immunological approach. Biochem
J. 1983;210(1):37-47.

21.

Pan BT, Teng K, Wu C, Adam M, Johnstone RM. Electron microscopic evidence
for externalization of the transferrin receptor in vesicular form in sheep
reticulocytes. J Cell Biol. 1985;101(3):942-8.

22.

Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle formation
during reticulocyte maturation. Association of plasma membrane activities with
released vesicles (exosomes). J Biol Chem. 1987;262(19):9412-20.

23.

Mitchell P, Petfalski E, Shevchenko A, Mann M, Tollervey D. The exosome: a
conserved eukaryotic RNA processing complex containing multiple 3'-->5'
exoribonucleases. Cell. 1997;91(4):457-66.

24.

Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et
al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med.
1996;183(3):1161-72.

25.

Subra C, Grand D, Laulagnier K, Stella A, Lambeau G, Paillasse M, et al.
Exosomes account for vesicle-mediated transcellular transport of activatable
phospholipases and prostaglandins. J Lipid Res. 2010;51(8):2105-20.

26.

Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic
exchange between cells. Nat Cell Biol. 2007;9(6):654-9.

28

27.

Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable
in serum and saliva is concentrated in exosomes. PLoS One. 2012;7(3):e30679.

28.

Salido-Guadarrama I, Romero-Cordoba S, Peralta-Zaragoza O, Hidalgo-Miranda
A, Rodriguez-Dorantes M. MicroRNAs transported by exosomes in body fluids as
mediators of intercellular communication in cancer. Onco Targets Ther.
2014;7:1327-38.

29.

Yellon DM, Davidson SM. Exosomes: nanoparticles involved in cardioprotection?
Circ Res. 2014;114(2):325-32.

30.

Johnsen KB, Gudbergsson JM, Skov MN, Pilgaard L, Moos T, Duroux M. A
comprehensive overview of exosomes as drug delivery vehicles - endogenous
nanocarriers for targeted cancer therapy. Biochim Biophys Acta. 2014;1846(1):7587.

31.

Xin H, Li Y, Chopp M. Exosomes/miRNAs as mediating cell-based therapy of
stroke. Front Cell Neurosci. 2014;8:377.

32.

Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular
vesicles for genetic information transfer and gene therapy. Hum Mol Genet.
2012;21(R1):R125-34.

33.

Gould SJ, Raposo G. As we wait: coping with an imperfect nomenclature for
extracellular vesicles. J Extracell Vesicles. 2013;2.

34.

Lotvall J, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C, et al. Minimal
experimental requirements for definition of extracellular vesicles and their
functions: a position statement from the International Society for Extracellular
Vesicles. J Extracell Vesicles. 2014;3:26913.

29

35.

Hess C, Sadallah S, Hefti A, Landmann R, Schifferli JA. Ectosomes released by
human neutrophils are specialized functional units. J Immunol. 1999;163(8):456473.

36.

Gasser O, Hess C, Miot S, Deon C, Sanchez JC, Schifferli JA. Characterisation
and properties of ectosomes released by human polymorphonuclear neutrophils.
Exp Cell Res. 2003;285(2):243-57.

37.

Kesimer M, Scull M, Brighton B, DeMaria G, Burns K, O'Neal W, et al.
Characterization of exosome-like vesicles released from human tracheobronchial
ciliated epithelium: a possible role in innate defense. FASEB J. 2009;23(6):185868.

38.

Kruger S, Abd Elmageed ZY, Hawke DH, Worner PM, Jansen DA, Abdel-Mageed
AB, et al. Molecular characterization of exosome-like vesicles from breast cancer
cells. BMC Cancer. 2014;14:44.

39.

Greco V, Hannus M, Eaton S. Argosomes: a potential vehicle for the spread of
morphogens through epithelia. Cell. 2001;106(5):633-45.

40.

Karlsson M, Lundin S, Dahlgren U, Kahu H, Pettersson I, Telemo E.
"Tolerosomes" are produced by intestinal epithelial cells. Eur J Immunol.
2001;31(10):2892-900.

41.

Ostman S, Taube M, Telemo E. Tolerosome-induced oral tolerance is MHC
dependent. Immunology. 2005;116(4):464-76.

42.

Arienti G, Carlini E, Saccardi C, Palmerini CA. Role of human prostasomes in the
activation of spermatozoa. J Cell Mol Med. 2004;8(1):77-84.

30

43.

Waldenstrom A, Genneback N, Hellman U, Ronquist G. Cardiomyocyte
microvesicles contain DNA/RNA and convey biological messages to target cells.
PLoS One. 2012;7(4):e34653.

44.

Maguire CA, Balaj L, Sivaraman S, Crommentuijn MH, Ericsson M, MinchevaNilsson L, et al. Microvesicle-associated AAV vector as a novel gene delivery
system. Mol Ther. 2012;20(5):960-71.

45.

Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B, et al. Membrane
vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol
Life Sci. 2011;68(16):2667-88.

46.

Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune
responses. Nat Rev Immunol. 2009;9(8):581-93.

47.

Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in
intercellular communication. J Proteomics. 2010;73(10):1907-20.

48.

van der Pol E, Boing AN, Harrison P, Sturk A, Nieuwland R. Classification,
functions, and clinical relevance of extracellular vesicles. Pharmacol Rev.
2012;64(3):676-705.

49.

S ELA, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: biology and
emerging therapeutic opportunities. Nat Rev Drug Discov. 2013;12(5):347-57.

50.

Zhang Z, Wang C, Li T, Liu Z, Li L. Comparison of ultracentrifugation and
density gradient separation methods for isolating Tca8113 human tongue cancer
cell line-derived exosomes. Oncol Lett. 2014;8(4):1701-6.

51.

Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more.
Trends Cell Biol. 2009;19(2):43-51.

31

52.

King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by
breast cancer cells. BMC Cancer. 2012;12:421.

53.

Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular
interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol.
2014;30:255-89.

54.

Lasser C, Alikhani VS, Ekstrom K, Eldh M, Paredes PT, Bossios A, et al. Human
saliva, plasma and breast milk exosomes contain RNA: uptake by macrophages. J
Transl Med. 2011;9:9.

55.

Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current
knowledge of their composition, biological functions, and diagnostic and
therapeutic potentials. Biochim Biophys Acta. 2012;1820(7):940-8.

56.

Welton JL, Khanna S, Giles PJ, Brennan P, Brewis IA, Staffurth J, et al.
Proteomics analysis of bladder cancer exosomes. Mol Cell Proteomics.
2010;9(6):1324-38.

57.

Atay S, Gercel-Taylor C, Kesimer M, Taylor DD. Morphologic and proteomic
characterization of exosomes released by cultured extravillous trophoblast cells.
Exp Cell Res. 2011;317(8):1192-202.

58.

Marimpietri D, Petretto A, Raffaghello L, Pezzolo A, Gagliani C, Tacchetti C, et
al. Proteome profiling of neuroblastoma-derived exosomes reveal the expression of
proteins potentially involved in tumor progression. PLoS One. 2013;8(9):e75054.

59.

Urbanelli L, Magini A, Buratta S, Brozzi A, Sagini K, Polchi A, et al. Signaling
pathways in exosomes biogenesis, secretion and fate. Genes (Basel).
2013;4(2):152-70.

32

60.

Roma-Rodrigues C, Fernandes AR, Baptista PV. Exosome in tumour
microenvironment: overview of the crosstalk between normal and cancer cells.
Biomed Res Int. 2014;2014:179486.

61.

Batista BS, Eng WS, Pilobello KT, Hendricks-Munoz KD, Mahal LK.
Identification of a conserved glycan signature for microvesicles. J Proteome Res.
2011;10(10):4624-33.

62.

Escrevente C, Grammel N, Kandzia S, Zeiser J, Tranfield EM, Conradt HS, et al.
Sialoglycoproteins and N-glycans from secreted exosomes of ovarian carcinoma
cells. PLoS One. 2013;8(10):e78631.

63.

Liang Y, Eng WS, Colquhoun DR, Dinglasan RR, Graham DR, Mahal LK.
Complex N-linked glycans serve as a determinant for exosome/microvesicle cargo
recruitment. J Biol Chem. 2014;289(47):32526-37.

64.

Choi DS, Kim DK, Kim YK, Gho YS. Proteomics, transcriptomics and lipidomics
of exosomes and ectosomes. Proteomics. 2013;13(10-11):1554-71.

65.

Choi DS, Kim DK, Kim YK, Gho YS. Proteomics of extracellular vesicles:
Exosomes and ectosomes. Mass Spectrom Rev. 2014.

66.

Ekstrom K, Valadi H, Sjostrand M, Malmhall C, Bossios A, Eldh M, et al.
Characterization of mRNA and microRNA in human mast cell-derived exosomes
and their transfer to other mast cells and blood CD34 progenitor cells. J Extracell
Vesicles. 2012;1.

67.

Baier SR, Nguyen C, Xie F, Wood JR, Zempleni J. MicroRNAs are absorbed in
biologically meaningful amounts from nutritionally relevant doses of cow milk and

33

affect gene expression in peripheral blood mononuclear cells, HEK-293 kidney
cell cultures, and mouse livers. J Nutr. 2014;144(10):1495-500.
68.

Batagov AO, Kurochkin IV. Exosomes secreted by human cells transport largely
mRNA fragments that are enriched in the 3'-untranslated regions. Biol Direct.
2013;8:12.

69.

Jenjaroenpun P, Kremenska Y, Nair VM, Kremenskoy M, Joseph B, Kurochkin
IV. Characterization of RNA in exosomes secreted by human breast cancer cell
lines using next-generation sequencing. PeerJ. 2013;1:e201.

70.

Taylor DD, Gercel-Taylor C. The origin, function, and diagnostic potential of
RNA within extracellular vesicles present in human biological fluids. Front Genet.
2013;4:142.

71.

Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al.
Glioblastoma microvesicles transport RNA and proteins that promote tumour
growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470-6.

72.

Liao J, Liu R, Yin L, Pu Y. Expression profiling of exosomal miRNAs derived
from human esophageal cancer cells by Solexa high-throughput sequencing. Int J
Mol Sci. 2014;15(9):15530-51.

73.

Boon RA, Vickers KC. Intercellular transport of microRNAs. Arterioscler Thromb
Vasc Biol. 2013;33(2):186-92.

74.

Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, et al.
HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial
cells. Nat Commun. 2014;5:3292.

34

75.

Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT.
MicroRNAs are transported in plasma and delivered to recipient cells by highdensity lipoproteins. Nat Cell Biol. 2011;13(4):423-33.

76.

Jovic M, Sharma M, Rahajeng J, Caplan S. The early endosome: a busy sorting
station for proteins at the crossroads. Histol Histopathol. 2010;25(1):99-112.

77.

Tamai K, Tanaka N, Nakano T, Kakazu E, Kondo Y, Inoue J, et al. Exosome
secretion of dendritic cells is regulated by Hrs, an ESCRT-0 protein. Biochem
Biophys Res Commun. 2010;399(3):384-90.

78.

Theos AC, Truschel ST, Tenza D, Hurbain I, Harper DC, Berson JF, et al. A
lumenal domain-dependent pathway for sorting to intralumenal vesicles of
multivesicular endosomes involved in organelle morphogenesis. Dev Cell.
2006;10(3):343-54.

79.

Stuffers S, Sem Wegner C, Stenmark H, Brech A. Multivesicular endosome
biogenesis in the absence of ESCRTs. Traffic. 2009;10(7):925-37.

80.

van Niel G, Charrin S, Simoes S, Romao M, Rochin L, Saftig P, et al. The
tetraspanin CD63 regulates ESCRT-independent and -dependent endosomal
sorting during melanogenesis. Dev Cell. 2011;21(4):708-21.

81.

Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al.
Ceramide triggers budding of exosome vesicles into multivesicular endosomes.
Science. 2008;319(5867):1244-7.

82.

Corrado C, Raimondo S, Chiesi A, Ciccia F, De Leo G, Alessandro R. Exosomes
as intercellular signaling organelles involved in health and disease: basic science
and clinical applications. Int J Mol Sci. 2013;14(3):5338-66.

35

83.

Morelli AE, Larregina AT, Shufesky WJ, Sullivan ML, Stolz DB, Papworth GD,
et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic
cells. Blood. 2004;104(10):3257-66.

84.

Svensson KJ, Christianson HC, Wittrup A, Bourseau-Guilmain E, Lindqvist E,
Svensson LM, et al. Exosome uptake depends on ERK1/2-heat shock protein 27
signaling and lipid Raft-mediated endocytosis negatively regulated by caveolin-1.
J Biol Chem. 2013;288(24):17713-24.

85.

Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the cellular uptake and
intracellular trafficking of exosomes by live-cell microscopy. J Cell Biochem.
2010;111(2):488-96.

86.

Tian T, Zhu YL, Hu FH, Wang YY, Huang NP, Xiao ZD. Dynamics of exosome
internalization and trafficking. J Cell Physiol. 2013;228(7):1487-95.

87.

Montecalvo A, Larregina AT, Shufesky WJ, Stolz DB, Sullivan ML, Karlsson JM,
et al. Mechanism of transfer of functional microRNAs between mouse dendritic
cells via exosomes. Blood. 2012;119(3):756-66.

88.

Tian T, Zhu YL, Zhou YY, Liang GF, Wang YY, Hu FH, et al. Exosome uptake
through clathrin-mediated endocytosis and macropinocytosis and mediating miR21 delivery. J Biol Chem. 2014;289(32):22258-67.

89.

Feng D, Zhao WL, Ye YY, Bai XC, Liu RQ, Chang LF, et al. Cellular
internalization of exosomes occurs through phagocytosis. Traffic. 2010;11(5):67587.

90.

Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle
uptake. J Extracell Vesicles. 2014;3.

36

91.

Parolini I, Federici C, Raggi C, Lugini L, Palleschi S, De Milito A, et al.
Microenvironmental pH is a key factor for exosome traffic in tumor cells. J Biol
Chem. 2009;284(49):34211-22.

92.

Sluijter JP, Verhage V, Deddens JC, van den Akker F, Doevendans PA.
Microvesicles and exosomes for intracardiac communication. Cardiovasc Res.
2014;102(2):302-11.

93.

Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, et al. Cellular
origins and thrombogenic activity of microparticles isolated from human
atherosclerotic plaques. J Am Coll Cardiol. 2007;49(7):772-7.

94.

Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C.
Microvesicles: mediators of extracellular communication during cancer
progression. J Cell Sci. 2010;123(Pt 10):1603-11.

95.

Loyer X, Vion AC, Tedgui A, Boulanger CM. Microvesicles as cell-cell
messengers in cardiovascular diseases. Circ Res. 2014;114(2):345-53.

96.

Stein JM, Luzio JP. Ectocytosis caused by sublytic autologous complement attack
on human neutrophils. The sorting of endogenous plasma-membrane proteins and
lipids into shed vesicles. Biochem J. 1991;274 ( Pt 2):381-6.

97.

Bucki R, Bachelot-Loza C, Zachowski A, Giraud F, Sulpice JC. Calcium induces
phospholipid redistribution and microvesicle release in human erythrocyte
membranes by independent pathways. Biochemistry. 1998;37(44):15383-91.

98.

VanWijk MJ, VanBavel E, Sturk A, Nieuwland R. Microparticles in
cardiovascular diseases. Cardiovasc Res. 2003;59(2):277-87.

37

99.

Sadallah S, Eken C, Martin PJ, Schifferli JA. Microparticles (ectosomes) shed by
stored human platelets downregulate macrophages and modify the development of
dendritic cells. J Immunol. 2011;186(11):6543-52.

100. Wang J, Chen S, Ma X, Cheng C, Xiao X, Chen J, et al. Effects of endothelial
progenitor cell-derived microvesicles on hypoxia/reoxygenation-induced
endothelial dysfunction and apoptosis. Oxid Med Cell Longev. 2013;2013:572729.
101. Weilner S, Schraml E, Redl H, Grillari-Voglauer R, Grillari J. Secretion of
microvesicular miRNAs in cellular and organismal aging. Exp Gerontol.
2013;48(7):626-33.
102. Baig S, Kothandaraman N, Manikandan J, Rong L, Ee KH, Hill J, et al. Proteomic
analysis of human placental syncytiotrophoblast microvesicles in preeclampsia.
Clin Proteomics. 2014;11(1):40.
103. Del Conde I, Shrimpton CN, Thiagarajan P, Lopez JA. Tissue-factor-bearing
microvesicles arise from lipid rafts and fuse with activated platelets to initiate
coagulation. Blood. 2005;106(5):1604-11.
104. Burton JO, Hamali HA, Singh R, Abbasian N, Parsons R, Patel AK, et al. Elevated
levels of procoagulant plasma microvesicles in dialysis patients. PLoS One.
2013;8(8):e72663.
105. Eken C, Martin PJ, Sadallah S, Treves S, Schaller M, Schifferli JA. Ectosomes
released by polymorphonuclear neutrophils induce a MerTK-dependent antiinflammatory pathway in macrophages. J Biol Chem. 2010;285(51):39914-21.
106. Sadallah S, Eken C, Schifferli JA. Ectosomes as modulators of inflammation and
immunity. Clin Exp Immunol. 2011;163(1):26-32.

38

107. Sadallah S, Eken C, Schifferli JA. Ectosomes as immunomodulators. Semin
Immunopathol. 2011;33(5):487-95.
108. Fevrier B, Raposo G. Exosomes: endosomal-derived vesicles shipping
extracellular messages. Curr Opin Cell Biol. 2004;16(4):415-21.
109. Frydrychowicz M, Kolecka-Bednarczyk A, Madejczyk M, Yasar S, Dworacki G.
Exosomes - structure, biogenesis and biological role in non-small-cell lung cancer.
Scand J Immunol. 2015;81(1):2-10.
110. Blanchard N, Lankar D, Faure F, Regnault A, Dumont C, Raposo G, et al. TCR
activation of human T cells induces the production of exosomes bearing the
TCR/CD3/zeta complex. J Immunol. 2002;168(7):3235-41.
111. Cocucci E, Meldolesi J. Ectosomes. Curr Biol. 2011;21(23):R940-1.
112. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause
release of membrane vesicles from the platelet surface that are enriched in the
membrane receptor for coagulation factor Va and express prothrombinase activity.
J Biol Chem. 1988;263(34):18205-12.
113. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet
prothrombinase complex is linked to vesiculation of the platelet plasma membrane.
Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. J
Biol Chem. 1989;264(29):17049-57.
114. Rauch S, Martin-Serrano J. Multiple interactions between the ESCRT machinery
and arrestin-related proteins: implications for PPXY-dependent budding. J Virol.
2011;85(7):3546-56.

39

115. Nabhan JF, Hu R, Oh RS, Cohen SN, Lu Q. Formation and release of arrestin
domain-containing protein 1-mediated microvesicles (ARMMs) at plasma
membrane by recruitment of TSG101 protein. Proc Natl Acad Sci U S A.
2012;109(11):4146-51.
116. Kuo L, Freed EO. ARRDC1 as a mediator of microvesicle budding. Proc Natl
Acad Sci U S A. 2012;109(11):4025-6.
117. Rautou PE, Mackman N. Del-etion of microvesicles from the circulation.
Circulation. 2012;125(13):1601-4.
118. Faille D, El-Assaad F, Mitchell AJ, Alessi MC, Chimini G, Fusai T, et al.
Endocytosis and intracellular processing of platelet microparticles by brain
endothelial cells. J Cell Mol Med. 2012;16(8):1731-8.
119. Dasgupta SK, Le A, Chavakis T, Rumbaut RE, Thiagarajan P. Developmental
endothelial locus-1 (Del-1) mediates clearance of platelet microparticles by the
endothelium. Circulation. 2012;125(13):1664-72.
120. Dasgupta SK, Abdel-Monem H, Niravath P, Le A, Bellera RV, Langlois K, et al.
Lactadherin and clearance of platelet-derived microvesicles. Blood.
2009;113(6):1332-9.
121. Marino G, Niso-Santano M, Baehrecke EH, Kroemer G. Self-consumption: the
interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol. 2014;15(2):81-94.
122. Strasser C, Grote P, Schauble K, Ganz M, Ferrando-May E. Regulation of nuclear
envelope permeability in cell death and survival. Nucleus. 2012;3(6):540-51.
123. Iglesias-Guimarais V, Gil-Guinon E, Sanchez-Osuna M, Casanelles E, GarciaBelinchon M, Comella JX, et al. Chromatin collapse during caspase-dependent

40

apoptotic cell death requires DNA fragmentation factor, 40-kDa subunit-/caspaseactivated deoxyribonuclease-mediated 3'-OH single-strand DNA breaks. J Biol
Chem. 2013;288(13):9200-15.
124. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in
apoptosis. J Immunol. 2004;172(11):6692-700.
125. Radic M. Clearance of Apoptotic Bodies, NETs, and Biofilm DNA: Implications
for Autoimmunity. Front Immunol. 2014;5:365.
126. Coleman ML, Sahai EA, Yeo M, Bosch M, Dewar A, Olson MF. Membrane
blebbing during apoptosis results from caspase-mediated activation of ROCK I.
Nat Cell Biol. 2001;3(4):339-45.
127. Sebbagh M, Renvoize C, Hamelin J, Riche N, Bertoglio J, Breard J. Caspase-3mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic
membrane blebbing. Nat Cell Biol. 2001;3(4):346-52.
128. Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok
VA, et al. C1q and mannose binding lectin engagement of cell surface calreticulin
and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med.
2001;194(6):781-95.
129. Dean WL, Lee MJ, Cummins TD, Schultz DJ, Powell DW. Proteomic and
functional characterisation of platelet microparticle size classes. Thromb Haemost.
2009;102(4):711-8.
130. Hristov M, Erl W, Linder S, Weber PC. Apoptotic bodies from endothelial cells
enhance the number and initiate the differentiation of human endothelial
progenitor cells in vitro. Blood. 2004;104(9):2761-6.

41

131. Crescitelli R, Lasser C, Szabo TG, Kittel A, Eldh M, Dianzani I, et al. Distinct
RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies,
microvesicles and exosomes. J Extracell Vesicles. 2013;2.
132. Akers JC, Gonda D, Kim R, Carter BS, Chen CC. Biogenesis of extracellular
vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic
bodies. J Neurooncol. 2013;113(1):1-11.
133. Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death
Differ. 2008;15(2):243-50.
134. Hochreiter-Hufford A, Ravichandran KS. Clearing the dead: apoptotic cell
sensing, recognition, engulfment, and digestion. Cold Spring Harb Perspect Biol.
2013;5(1):a008748.
135. Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD,
et al. Internalization of circulating apoptotic cells by splenic marginal zone
dendritic cells: dependence on complement receptors and effect on cytokine
production. Blood. 2003;101(2):611-20.
136. Li J, Fang L, Meyer P, Killer HE, Flammer J, Neutzner A. Anti-inflammatory
response following uptake of apoptotic bodies by meningothelial cells. J
Neuroinflammation. 2014;11:35.
137. Holmgren L, Szeles A, Rajnavolgyi E, Folkman J, Klein G, Ernberg I, et al.
Horizontal transfer of DNA by the uptake of apoptotic bodies. Blood.
1999;93(11):3956-63.

42

138. Bergsmedh A, Szeles A, Henriksson M, Bratt A, Folkman MJ, Spetz AL, et al.
Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad
Sci U S A. 2001;98(11):6407-11.
139. van den Boorn JG, Dassler J, Coch C, Schlee M, Hartmann G. Exosomes as
nucleic acid nanocarriers. Adv Drug Deliv Rev. 2013;65(3):331-5.
140. Lemay JF, Larochelle M, Marguerat S, Atkinson S, Bahler J, Bachand F. The RNA
exosome promotes transcription termination of backtracked RNA polymerase II.
Nat Struct Mol Biol. 2014;21(10):919-26.
141. Muller G, Schneider M, Biemer-Daub G, Wied S. Microvesicles released from rat
adipocytes and harboring glycosylphosphatidylinositol-anchored proteins transfer
RNA stimulating lipid synthesis. Cell Signal. 2011;23(7):1207-23.
142. Izumi H, Kosaka N, Shimizu T, Sekine K, Ochiya T, Takase M. Bovine milk
contains microRNA and messenger RNA that are stable under degradative
conditions. J Dairy Sci. 2012;95(9):4831-41.
143. Sun Q, Chen X, Yu J, Zen K, Zhang CY, Li L. Immune modulatory function of
abundant immune-related microRNAs in microvesicles from bovine colostrum.
Protein Cell. 2013;4(3):197-210.
144. Baier S, Howard K, Cui J, Shu J, Zempleni J. MicroRNAs in chicken eggs are
bioavailable in healthy adults and can modulate mRNA expression in peripheral
blood mononuclear cells. The FASEB Journal. 2015;29(1 Supplement).
145. Pan BT, Johnstone R. Selective externalization of the transferrin receptor by sheep
reticulocytes in vitro. Response to ligands and inhibitors of endocytosis. J Biol
Chem. 1984;259(15):9776-82.

43

146. Skokos D, Botros HG, Demeure C, Morin J, Peronet R, Birkenmeier G, et al. Mast
cell-derived exosomes induce phenotypic and functional maturation of dendritic
cells and elicit specific immune responses in vivo. J Immunol. 2003;170(6):303745.
147. Utsugi-Kobukai S, Fujimaki H, Hotta C, Nakazawa M, Minami M. MHC class Imediated exogenous antigen presentation by exosomes secreted from immature
and mature bone marrow derived dendritic cells. Immunol Lett. 2003;89(2-3):12531.
148. Quah BJ, O'Neill HC. The immunogenicity of dendritic cell-derived exosomes.
Blood Cells Mol Dis. 2005;35(2):94-110.
149. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell.
2009;136(2):215-33.
150. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14. Cell.
1993;75(5):843-54.
151. Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al.
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis
elegans. Nature. 2000;403(6772):901-6.
152. Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, et al.
Conservation of the sequence and temporal expression of let-7 heterochronic
regulatory RNA. Nature. 2000;408(6808):86-9.
153. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans.
Science. 2001;294(5543):862-4.

44

154. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of
mammalian microRNA targets. Cell. 2003;115(7):787-98.
155. Mack GS. MicroRNA gets down to business. Nat Biotechnol. 2007;25(6):631-8.
156. Xu W, San Lucas A, Wang Z, Liu Y. Identifying microRNA targets in different
gene regions. BMC Bioinformatics. 2014;15 Suppl 7:S4.
157. Mochizuki K, Fine NA, Fujisawa T, Gorovsky MA. Analysis of a piwi-related
gene implicates small RNAs in genome rearrangement in tetrahymena. Cell.
2002;110(6):689-99.
158. Ambros V, Lee RC, Lavanway A, Williams PT, Jewell D. MicroRNAs and other
tiny endogenous RNAs in C. elegans. Curr Biol. 2003;13(10):807-18.
159. Shukla GC, Singh J, Barik S. MicroRNAs: Processing, Maturation, Target
Recognition and Regulatory Functions. Mol Cell Pharmacol. 2011;3(3):83-92.
160. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell.
2004;116(2):281-97.
161. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are
transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051-60.
162. Bortolin-Cavaille ML, Dance M, Weber M, Cavaille J. C19MC microRNAs are
processed from introns of large Pol-II, non-protein-coding transcripts. Nucleic
Acids Res. 2009;37(10):3464-73.
163. Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A. Identification of
mammalian microRNA host genes and transcription units. Genome Res.
2004;14(10A):1902-10.

45

164. Dey BK, Pfeifer K, Dutta A. The H19 long noncoding RNA gives rise to
microRNAs miR-675-3p and miR-675-5p to promote skeletal muscle
differentiation and regeneration. Genes Dev. 2014;28(5):491-501.
165. Gangaraju VK, Lin H. MicroRNAs: key regulators of stem cells. Nat Rev Mol Cell
Biol. 2009;10(2):116-25.
166. Meister G. Argonaute proteins: functional insights and emerging roles. Nat Rev
Genet. 2013;14(7):447-59.
167. Fu Q, Wang PJ. Mammalian piRNAs: Biogenesis, function, and mysteries.
Spermatogenesis. 2014;4:e27889.
168. Weick EM, Miska EA. piRNAs: from biogenesis to function. Development.
2014;141(18):3458-71.
169. Borchert GM, Lanier W, Davidson BL. RNA polymerase III transcribes human
microRNAs. Nat Struct Mol Biol. 2006;13(12):1097-101.
170. Liu X, Fortin K, Mourelatos Z. MicroRNAs: Biogenesis and Molecular Functions.
Brain Pathology. 2008;18(1):113-21.
171. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha
initiates microRNA processing. Nature. 2003;425(6956):415-9.
172. Denli AM, Tops BB, Plasterk RH, Ketting RF, Hannon GJ. Processing of primary
microRNAs by the Microprocessor complex. Nature. 2004;432(7014):231-5.
173. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex
in primary microRNA processing. Genes Dev. 2004;18(24):3016-27.

46

174. Yeom KH, Lee Y, Han J, Suh MR, Kim VN. Characterization of DGCR8/Pasha,
the essential cofactor for Drosha in primary miRNA processing. Nucleic Acids
Res. 2006;34(16):4622-9.
175. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of
pre-microRNAs and short hairpin RNAs. Genes Dev. 2003;17(24):3011-6.
176. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of
microRNA precursors. Science. 2004;303(5654):95-8.
177. Zeng Y, Cullen BR. Structural requirements for pre-microRNA binding and
nuclear export by Exportin 5. Nucleic Acids Res. 2004;32(16):4776-85.
178. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate
ribonuclease in the initiation step of RNA interference. Nature.
2001;409(6818):363-6.
179. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin
RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes
Dev. 2002;16(8):948-58.
180. Zhang H, Kolb FA, Jaskiewicz L, Westhof E, Filipowicz W. Single processing
center models for human Dicer and bacterial RNase III. Cell. 2004;118(1):57-68.
181. Gurtan AM, Lu V, Bhutkar A, Sharp PA. In vivo structure-function analysis of
human Dicer reveals directional processing of precursor miRNAs. RNA.
2012;18(6):1116-22.
182. Cipolla GA. A non-canonical landscape of the microRNA system. Front Genet.
2014;5:337.

47

183. Cerutti L, Mian N, Bateman A. Domains in gene silencing and cell differentiation
proteins: the novel PAZ domain and redefinition of the Piwi domain. Trends
Biochem Sci. 2000;25(10):481-2.
184. Carmell MA, Xuan Z, Zhang MQ, Hannon GJ. The Argonaute family: tentacles
that reach into RNAi, developmental control, stem cell maintenance, and
tumorigenesis. Genes Dev. 2002;16(21):2733-42.
185. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a
link between genetic and biochemical analyses of RNAi. Science.
2001;293(5532):1146-50.
186. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and
22-nucleotide RNAs. Genes Dev. 2001;15(2):188-200.
187. Janas MM, Wang B, Harris AS, Aguiar M, Shaffer JM, Subrahmanyam YV, et al.
Alternative RISC assembly: binding and repression of microRNA-mRNA
duplexes by human Ago proteins. RNA. 2012;18(11):2041-55.
188. Pillai RS, Artus CG, Filipowicz W. Tethering of human Ago proteins to mRNA
mimics the miRNA-mediated repression of protein synthesis. RNA.
2004;10(10):1518-25.
189. Eckhardt S, Szostak E, Yang Z, Pillai R. Artificial tethering of Argonaute proteins
for studying their role in translational repression of target mRNAs. Methods Mol
Biol. 2011;725:191-206.
190. Kiriakidou M, Tan GS, Lamprinaki S, De Planell-Saguer M, Nelson PT,
Mourelatos Z. An mRNA m7G cap binding-like motif within human Ago2
represses translation. Cell. 2007;129(6):1141-51.

48

191. Meister G. miRNAs get an early start on translational silencing. Cell.
2007;131(1):25-8.
192. Hock J, Meister G. The Argonaute protein family. Genome Biol. 2008;9(2):210.
193. Thermann R, Hentze MW. Drosophila miR2 induces pseudo-polysomes and
inhibits translation initiation. Nature. 2007;447(7146):875-8.
194. Wakiyama M, Takimoto K, Ohara O, Yokoyama S. Let-7 microRNA-mediated
mRNA deadenylation and translational repression in a mammalian cell-free
system. Genes Dev. 2007;21(15):1857-62.
195. Eulalio A, Huntzinger E, Izaurralde E. GW182 interaction with Argonaute is
essential for miRNA-mediated translational repression and mRNA decay. Nat
Struct Mol Biol. 2008;15(4):346-53.
196. Zekri L, Huntzinger E, Heimstadt S, Izaurralde E. The silencing domain of
GW182 interacts with PABPC1 to promote translational repression and
degradation of microRNA targets and is required for target release. Mol Cell Biol.
2009;29(23):6220-31.
197. Eulalio A, Huntzinger E, Izaurralde E. Getting to the root of miRNA-mediated
gene silencing. Cell. 2008;132(1):9-14.
198. Gu S, Kay MA. How do miRNAs mediate translational repression? Silence.
2010;1(1):11.
199. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, et al. Biological
functions of miR-29b contribute to positive regulation of osteoblast differentiation.
J Biol Chem. 2009;284(23):15676-84.

49

200. Franceschetti T, Kessler CB, Lee SK, Delany AM. miR-29 promotes murine
osteoclastogenesis by regulating osteoclast commitment and migration. J Biol
Chem. 2013;288(46):33347-60.
201. Ding W, Dang H, You H, Steinway S, Takahashi Y, Wang HG, et al. miR-200b
restoration and DNA methyltransferase inhibitor block lung metastasis of
mesenchymal-phenotype hepatocellular carcinoma. Oncogenesis. 2012;1:e15.
202. Hung CS, Liu HH, Liu JJ, Yeh CT, Chang TC, Wu CH, et al. MicroRNA-200a and
-200b mediated hepatocellular carcinoma cell migration through the epithelial to
mesenchymal transition markers. Ann Surg Oncol. 2013;20 Suppl 3:S360-8.
203. Wong CM, Wei L, Au SL, Fan DN, Zhou Y, Tsang FH, et al. MiR-200b/200c/429
subfamily negatively regulates Rho/ROCK signaling pathway to suppress
hepatocellular carcinoma metastasis. Oncotarget. 2015.
204. Hou Y, Wang X, Chen Y, Mu S. MicroRNA-145 as ideal biomarker for the
diagnosis of various carcinomas. Tumour Biol. 2015;36(4):2641-9.
205. Wu C, Liu Q, Liu B. MicroRNA-155 Hallmarks Promising Accuracy for the
Diagnosis of Various Carcinomas: Results from a Meta-Analysis. Dis Markers.
2015;2015:327287.
206. van Wijnen AJ, van de Peppel J, van Leeuwen JP, Lian JB, Stein GS, Westendorf
JJ, et al. MicroRNA functions in osteogenesis and dysfunctions in osteoporosis.
Curr Osteoporos Rep. 2013;11(2):72-82.
207. Pescador N, Perez-Barba M, Ibarra JM, Corbaton A, Martinez-Larrad MT,
Serrano-Rios M. Serum circulating microRNA profiling for identification of
potential type 2 diabetes and obesity biomarkers. PLoS One. 2013;8(10):e77251.

50

208. Wang F, Long G, Zhao C, Li H, Chaugai S, Wang Y, et al. Plasma microRNA133a is a new marker for both acute myocardial infarction and underlying coronary
artery stenosis. J Transl Med. 2013;11:222.
209. Fazi F, Nervi C. MicroRNA: basic mechanisms and transcriptional regulatory
networks for cell fate determination. Cardiovasc Res. 2008;79(4):553-61.
210. Zhang L, Hou D, Chen X, Li D, Zhu L, Zhang Y, et al. Exogenous plant MIR168a
specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation
by microRNA. Cell Res. 2012;22(1):107-26.
211. Dickinson B, Zhang Y, Petrick JS, Heck G, Ivashuta S, Marshall WS. Lack of
detectable oral bioavailability of plant microRNAs after feeding in mice. Nat
Biotechnol. 2013;31(11):965-7.
212. Snow JW, Hale AE, Isaacs SK, Baggish AL, Chan SY. Ineffective delivery of dietderived microRNAs to recipient animal organisms. RNA Biol. 2013;10(7):110716.
213. Witwer KW, McAlexander MA, Queen SE, Adams RJ. Real-time quantitative
PCR and droplet digital PCR for plant miRNAs in mammalian blood provide little
evidence for general uptake of dietary miRNAs: limited evidence for general
uptake of dietary plant xenomiRs. RNA Biol. 2013;10(7):1080-6.
214. Kosaka N, Izumi H, Sekine K, Ochiya T. microRNA as a new immune-regulatory
agent in breast milk. Silence. 2010;1(1):7.
215. Aqil F, Munagala R, Jeyabalan J, Gupta RC. Abstract 5407: Milk derived
exosomes: Scalable source of biologically active drug delivery nanoparticles.
Cancer Research. 2014;74(19 Supplement):5407.

51

Chapter 2
Transport of Bovine Milk Exosomes in
Human Endothelial Cells

52

Human endothelial cells transport foreign exosomes from cow’s milk by
endocytosis1,2
Rio Jati Kusuma3, Taylor Friemel4, Janos Zempleni*3
Last names underlined
3

Department of Nutrition and Health Science, University of Nebraska-Lincoln, Lincoln,

NE
4

Department of Biochemistry, University of Nebraska-Lincoln, Lincoln, NE

*Corresponding Author: Janos Zempleni; jzempleni2@unl.edu; 316C Leverton Hall,
Lincoln, NE 68583-0806, USA

1

Supported by NIH 1P20GM104320, NIFA 2015-67017-23181, the Egg Nutrition

Center, the Gerber Foundation, the University of Nebraska Agricultural Research
Division (Hatch Act), and USDA multistate group W3002.
2

Author disclosures: R. J. Kusuma, T. Friemel, and J. Zempleni, no conflicts of interest.

53

ABSTRACT
MicroRNAs (miRNAs) can be synthesized endogenously and cause gene repression.
Encapsulation of miRNAs in exosomes confers protection against degradation and a
vehicle for shuttling between cells and tissues, and cellular uptake by endocytosis.
Exosomes can be found in biological fluids and foods including milk. Evidence suggests
that humans absorb cow’s milk exosomes and deliver the microRNA cargo to peripheral
tissues, consistent with gene regulation by nucleic acids across species boundaries. There
is strong evidence that milk exosomes may cross the mucosa without re-packaging in
mice. Here, we tested the hypothesis that human vascular endothelial cells transport milk
exosomes by endocytosis, as a crucial step toward delivery of dietary microRNAs to
peripheral tissues. Studies were conducted using human umbilical vein endothelial cells
and fluorophore-labeled exosomes isolated from cow’s milk. Exosome uptake followed
Michaelis-Menten kinetics (Vmax = 0.057±0.004 ng exosome protein x 40,000 cells-1 x
hour-1; Km= 17.97±3.84 µg protein/200 µl media) and decreased by 80% when the
incubation temperature was lowered from 37°C to 4°C, consistent with carrier-mediated
transport. When exosome surface proteins were removed by treatment with proteinase K
or transport measured in the presence of carbohydrate competitors, transport rates
decreased by 30% to 50% compared with controls, consistent with a role of surface
glycoproteins in endothelial transport. Treatment with cytochalasin D caused a 50%
decrease in transport, consistent with endocytosis. We conclude that human endothelial
cells transport bovine exosomes by endocytosis and propose that this is an important step
in the delivery of exosome cargo to peripheral tissues.
Keyword: endocytosis; endothelial cell; extracellular vesicles; milk exosomes; uptake

54

INTRODUCTION
MicroRNAs (miRNAs) are small non coding RNA, which are encoded by their own
genes, or introns and exons of long nonprotein-coding transcripts (1-3); miRNAs may
silence genes via destabilizing of messenger RNA or preventing translation of mRNA (4,
5). The online database miRBase, release 21, lists 1881 “high confidence” human
miRNAs (6, 7), and about 60% of the miR-binding sites in the human genome are
evolutionary conserved (8). Gene regulations by miRNAs has been implicated in
numerous physiological (9) and pathological (10) conditions in humans.
Until recently, miRNAs have been considered endogenous regulators of genes,
i.e., miRNAs synthesized in a given organism regulate the expression of genes in that
host. In a recent publication we have refuted this paradigm and provided strong evidence
that 1) humans absorb biologically meaningful amounts of miRNAs from nutritionally
relevant doses of cow's milk, 2) milk miRNAs are delivered to peripheral human tissues,
3) physiological concentrations of milk miRNAs affect human gene expression in vivo
and in cell cultures, and 4) endogenous synthesis of miRNAs does not compensate for
dietary miRNAs deficiency in mice (11). That paper was the first report suggesting that
miRNAs can be transferred between distinct animal species through dietary means. Our
discoveries were corroborated in a recent report by investigators from the NIH-supported
Genboree database who detected numerous dietary miRNAs in 6.8 billion sequencing
reads from 528 human samples (12). Note that mammalian miRNAs are encapsulated in
extracellular vesicles such as exosomes, thereby confer protection against degradation
(13-16) and a pathway for cellular uptake by endocytosis (17, 18). Studies by us and an
independent laboratory suggest that human and rat intestinal cells transport cow's milk
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exosomes by endocytosis (Wolf, 2015, unpublished materials) and that milk exosomes
may cross the intestinal mucosa without re-packaging in mice and enter circulation in
intact form (19).
Here we tested the hypothesis that human endothelial cells transport cow's milk
exosomes by a carrier-mediated process similar to the mechanism reported for the uptake
of exosomes in intestinal cells. The uptake of dietary exosomes into endothelial cells is
an important step in regulation of genes in peripheral tissues by dietary miRNAs in
humans.

Materials and methods
Exosomes isolation and characterization
Cow's milk (1% fat) was obtained from a local grocery store in Lincoln,
Nebraska. Milk was centrifuged at 12,000 x g at 4°C for 30 minutes to remove somatic
cells and debris. Fat-free supernatant was mixed with an equal volume of 0.25 M EDTA
(pH 7.0) and incubated on ice for 15 minutes to precipitate casein (20). The suspension
was ultracentrifuged at 80,000 x g at 4°C for 60 minutes (Sorvall WX Ultra 80, F37L8x100 rotor; Thermo Scientific, USA) to remove precipitated protein, milk fat globules,
and microvesicles larger than exosomes. Exosomes were precipitated by centrifugation at
120,000 x g at 4°C for 90 minutes. The exosome pellet was re-suspended in sterile
phosphate-buffered saline and filtered through a 0.22-µm membrane filter (Milex).
Sodium azide was added to produce a final concentration of 0.01% and exosomes were
stored at 4°C for up to 5 days.
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Exosome purity and absence of aggregation was assessed as recommended by the
International Society for Extracellular Vesicles (21). Briefly, whole protein extract from
exosomes were resolved by gel electrophoresis (10 µg protein/lane) as described
previously (22) and membranes were probed using mouse anti-bovine CD63 (AbD
Serotec, UK) as a marker for exosomes, rabbit anti-serum to bovine alpha s1-casein as a
marker for the species of exosome origin, and goat anti-bovine histone H3(Santa Cruz
Biotechnology, USA) as a negative control (all at 1,000-fold dilutions). Bands were
visualized using an Odyssey infrared imaging system (Licor, Inc.) and IRDye 800CWlabeled secondary antibodies (50,000-fold dilution). Anti-bovine alpha s1-casein was
raised in rabbits (Cocalico, Inc, USA) using AHSMKEGIHAQQKEPMIGVGC coupled
to keyhole limpet hemocyanin through amidated C-terminal and acetylated N-terminus as
described previously (23). The anti-serum, but not pre-immunization serum, produced
bands of the expected size with cow’s milk and the synthetic peptide antigen, but did not
react with human breast milk (Online Supplementary Fig. 1). Absence of exosome
aggregation in our preparations was confirmed using negative staining transmission
electron microscopy (Hitachi H7500, Japan) in the Microscopy Core Facility in the
University of Nebraska-Lincoln. ImageJ (http://imagej.nih.gov/ij/index.html) was used to
analyze the particle size of exosomes.
Fluorophore conjugation
Exosomes were labeled with FM-464 (Molecular Probes) as described previously
(24). Unbound fluorophore was removed by pelleting the exosomes at 120,000 x g for 90
minutes, followed by three wash and ultracentrifugation cycles with sterile phosphatebuffered saline. The concentration of exosome protein was measured using a Nanodrop-
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1000 spectrophotometer (NanoDrop Technologies, Inc., USA) and diluted into F-12K
media at the desired protein concentration.
Cell culture
Human umbilical vein endothelial cells (HUVEC, passages 38-45) were
purchased from American Type Culture Collection (CRL-1730) and cultured in F-12K
medium, supplemented with 0.04 mg/ml endothelial cell growth supplement (Sigma), 0.1
mg/ml heparin (Sigma), 10,000 units of penicillin, 10 mg of streptomycin and 10%
exosomes-free fetal bovine serum in a humidified atmosphere at 5% CO2 and 37° C.
Exosome-free fetal bovine serum was prepared by sonicating the serum in a water bath
for 1 hour, which destroyed most of the marker miRNA present in FBS (Online
Supplementary Fig. 2). Media was replaced with fresh media every 48 hours.
Transport studies
In a typical experiment, 15x103 HUVECs were seeded per well in a 96-well plate
and allowed to adhere overnight. . Fluorophore-labeled exosomes were added to the wells
to produce the desired concentration of exosome protein. Cells were incubated for the
length of time denoted in Results. Media were removed and cells were washed three
times with sterile PBS to remove extracellular exosomes. Controls were prepared by
washing the cells immediately after addition of exosomes. Cell fluorescence (560/645
nm) was measured in a microplate spectrophotometer (BioTek, USA). Cells were
harvested using trypsin and counted using a hemocytometer. Units of fluorescence were
converted into mass of exosome transported by labeling a known mass of exosomes
(protein) with fluorophore, and quantifying the fluorescence after removing unbound
fluorophore. In select experiments, we measured the effects of the following treatments
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on exosome transport: 1) cells were treated with 5 or 10 µg/mL of endocytosis inhibitor
cytochalasin D (Gibco) for 30 minutes before adding exosomes (25); 2) cells were treated
with 150 mM carbohydrate competitors D-glucose or D-galactose for 30 minutes before
adding exosomes (26); and exosomes were treated with 100 µg/mL of proteinase K at
37°C for 30 minutes to remove surface proteins (18). All assays were performed in
triplicate in at least three independent experiments. Transport kinetics were modeled
using the Michaelis-Menten equation and non-linear regression; modeling was conducted
using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA).
Statistical Analysis
Means±standard deviations are reported. Homogeneity of variances among
groups confirmed using Bartlett’s test (27, 28). Statistical significance of differences
among treatment groups was assessed using one-way ANOVA and Tukey-Kramer post
hoc test. Analyses were performed in GraphPad Prism 6.0 (GraphPad Software, La Jolla,
CA, USA). Differences were considered significant if p<0.05.

Results
Our exosome purification protocol yielded preparations of non-aggregated
extracellular vesicles that were primarily composed of exosomes. When protein extracts
were probed with anti-CD63 or anti-bovine alpha s1-casein strong bands were observed
in western blots; in contrast, when protein extracts were probed with anti-histone H3
(negative control) no band was visible (Fig. 1A). The particle suspension was largely free
of aggregates and the shape and contour of exosomes suggested vesicle integrity (Fig.
1B) with the particle size of 69±19.5 in diameter as expected for exosomes (29).
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The uptake of milk exosomes into HUVECs is a carrier-mediated process. First,
we established that exosomes uptake was linear with time up to one hour if 70 µg
exosome protein was added to 200 µL media (Figure 2A), i.e. concentration below
transporter saturation (see below). Subsequent transport studies were carried out using an
incubation time of one hour. Exosome uptake followed Michaelis-Menten kinetics
(Figure 2B): Vmax=0.057±0.004 ng exosome protein x 40,000 cells-1 x hour-1 and Km=
18.0±3.84 µg exosome protein/200 µL media. Exosomes uptake depended on the
incubation temperature (Fig. 3). When a 5-fold excess (equaling to 6 times Km) of
unlabeled exosomes as added to the cell cultures, the uptake of fluorophore-conjugated
exosomes decreased to 16.83±0.07 % of control (P<0.05, n=3 biological replicates each
measured in triplicates). When cells were treated with 5 or 10 µg/ml, exosome uptake
decreased to 63.5±21.3% and 40.8±22.0%, respectively, of controls, consistent with
endocytosis.
Surface proteins played an important role in facilitating exosome uptake into
HUVECs. When exosomal surface proteins were removed by treatment with proteinase
K, exosome uptake decreased to about 50% of controls (Fig. 4A). The carbohydrate
competitor galactose, but not glucose, caused a significant decrease in exosome uptake
(Fig. 4B).

Discussion
Evidence is accumulating in support of the theory that dietary miRNAs may cross
the intestinal mucosa and has biological activity in humans (11, 12, 19, 30). However, the
mechanisms of intestinal transport and subsequent delivery to tissues are unknown. To
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the best of our knowledge, this is the first paper to propose that the transport of cow’s
milk exosomes across vascular endothelial cells is mediated by endocytosis and that
proteins on the surface of milk exosomes are compatible with proteins on the surface of
human vascular endothelial cells. This study further corroborates the notion that dietary
miRNAs have biological activity in humans.
This study has far-reaching implications for human nutrition and health. The
National Cancer Institute defines bioactive compounds as “a type of chemical found in
small amounts in plants and certain foods […]. Bioactive compounds have actions in the
body that may promote good health. They are being studied in the prevention of […]
diseases” (31). Milk miRNAs meet that definition, based on our previous studies (11).
Future studies will need to reveal the extent to which dietary miRNAS contribute to the
total miRNA body pool.
miRNAs have been implicated in virtually all aspects of human health and disease
including bone health (32, 33), female and male reproduction (34, 35), arthritis and
inflammatory bowel disease (36-38), metabolic syndrome (39-42), and cancer (43). Note
that miRNAs also may have effects detrimental to human health. For example, the
plasma concentrations of miR-210 are significantly higher in patients with pancreatic
cancer compared with healthy controls (44), plasma miR-141 and miR-25 are elevated in
prostate cancer and esophageal squamous cell carcinoma, respectively (45); plasma miR21 is elevated in various types of cancer (46); and the urinary excretion of miR-126 and
miR-182 is greater in bladder cancer patients compared with healthy controls (47).
Additional areas of health relevance include the possible use of milk exosomes as
vehicle for the oral delivery of unstable drugs, and the potential role of dietary miRNAs
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as confounders in biomarker studies that rely on miRNAs in body fluids. Evidence
suggests that that dietary preferences affect miRNA signatures in human plasma (48).
Some uncertainties remain and will need to be addressed in future studies. First,
the identities of the glycoproteins that mediates endocytosis of milk exosomes in
endothelial cells is unknown and is an area of investigation in our laboratory. Second, it
is possible that an excess of endogenous exosomes might compete with the endocytosis
of dietary exosomes. We cannot assess this possibility until the plasma concentration of
dietary exosomes has been established; distinct glycoproteome profiles on the surfaces of
cells from distinct tissues might be a confounder in such studies. Third, our studies did
not formally exclude the remote possibility that adherence to cells, rather than uptake into
cells, accounted for cell fluorescence. We consider the mere adhesion of exosomes to cell
surfaces an unlikely scenario, based on previous studies suggesting that milk exosomes
may cross the intestinal mucosa without re-packaging in mice and enter circulation in
intact form (19). Also, our own studies of intestinal transport of milk exosomes in human
and rat cell cultures suggest that exosomes are endocytosed at the apical membrane for
subsequent secretion across the basolateral membrane. Fourth, it is unknown whether
dietary exosomes from species remotely related will be recognized by surface proteins in
human cells.
We conclude that this study provides an important mechanistic framework for
future studies of dietary extracellular vesicles and the roles of dietary miRNAs in human
health and disease. In particular, due to the controversy surrounding the bioavailability of
plant-borne miRNAs in humans, resources need to be devoted to this promising field of
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research. A representative example would be the identification and validation of
molecular signatures for assessing the dietary intake of vesicles and their cargo.

ABBREVIATIONS USED
miR, microRNA; miRNA, microRNA; HUVEC, human umbilical vein endotelial cells
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A)

B)

FIGURE 2.1. A: western blot result showing the absence of intercellular protein histone
H3 but positive for commonly enriched exosomal protein; CD63 and bovine protein
origin; alpha s1-casein. B: electron microscopy images of cow’s milk exosomes showing
round shape (69±19.5 nm) and intact vesicles.
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FIGURE 2.2. Milk exosomes uptake is time (A) and dose (B) dependent (n=9, 3
independent replicates).
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Chapter 3
Loss of miRNAs during Processing and
Storage of Cows (Bos taurus) Milk
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ABSTRACT
MicroRNAs (miRs, miRNAs) play central roles in gene regulation. Previously, we
reported that miRNAs from pasteurized, store-bought bovine milk have biological
activity in humans. Here we assessed the effects of milk processing, storage, somatic cell
content, and handling by consumers on the degradation of miRNAs in milk; we also
quantified miRNAs in dairy products. Pasteurization and homogenization caused a 63%
loss of miR-200c, whereas a 67% loss observed for miR-29b was statistically significant
only in skim milk. Effects of cold storage and somatic cell content were quantitatively
minor (<2% loss). Heating in the microwave caused a 40% loss of miR-29b but no loss of
miR-200c. Milk fat content had no effect on miRNA stability during storage and
microwave heating. The concentrations of miRNAs in dairy products were considerably
lower than in store-bought milk. We conclude that processing of milk by dairies and
handling by consumers causes a significant loss of miRNAs.

Key words: heating, MiRNAs, milk, processing, storage
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INTRODUCTION
MicroRNAs (miRs, miRNAs) are small non-coding RNAs that play essential roles in the
regulation of genes at the posttranscriptional level in plants and animals.1 Mature
miRNAs are about 22 nucleotides long and bind to complementary sequences in the 3’untranslated region of mRNAs. Perfect or near perfect base pairing of the miRNAs and
its target mRNAs typically results in mRNAs degradation, whereas less perfect base
pairing typically results in inhibition of mRNAs translation.2-3 Traditionally, miRNAs
have been considered endogenous regulators of genes, i.e., miRNAs synthesized by a
given host regulate the expression of genes in that host. Recently, our laboratory refuted
this paradigm. We provided strong evidence that 1) humans absorb biologically
meaningful amounts of miRNAs from nutritionally relevant doses of cow’s milk, 2)
physiological concentrations of milk miRNAs affect human gene expression in vivo and
in cell cultures, and 3) endogenous synthesis of miRNAs does not compensate for dietary
miRNA deficiency in mice.4 Our discoveries were largely modeled on miR-29b and miR200c, but likely hold true for all miRNAs encapsulated in milk exosomes.5-6 To the best
of our knowledge, our previous paper is the first to provide unambiguous evidence that
miRNAs can be transferred between distinct species through dietary means. In contrast,
previous claims that miRNAs from plants affect human gene expression7-8 are highly
controversial and were met with skepticism by the scientific community.4, 9-12 Based on
the above observations, milk miRNAs are a novel class of bioactive food compounds as
defined by the National Cancer Institute in the United States.13 The discovery that milk
miRNAs are bioactive food compounds has broader implications as miRNAs play
essential roles in gene regulation,2-3 cell communication,14-15 and human health.16-23
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This study focused on determining the effect of milk processing, storage, somatic
cell content, and handling by consumers on two miRNAs, miR-29b and miR-200c levels
based on the following rationale. In bovine milk, miR-29b and miR-200c are among the
most abundant miRNAs.20 MiR-29b is an important regulator of bone mineralization in
humans, as it increases osteoblast differentiation16 and decreases osteoclast differentiation
and function.17 MiR-200c decreases cancer risk by targeting the transcription factor
ZEB1, which induces E-cadherin expression, thereby limiting epithelial-to-mesenchymal
transition, a key event in metastasis.24-25 Also, the nucleotide sequences of miR-29b and
miR-200c in bovine milk are identical to those of their human orthologs.26 Our rationale
for including the somatic cell count in our analysis was to assess whether an increase in
milk cells, as seen in mastitis, might be a confounder in the analysis of milk miRNAs.
In Western societies, the majority of milk is processed prior to consumption. In fact,
the production and sale of raw milk dairy products is illegal in many states in the United
States and pasteurization is required.27 Moreover, while the per capita consumption of
milk has declined from 236 pounds in 1982 to 195 pounds in 2012, total dairy
consumption increased by 11% during the same time period.28 Therefore, we considered
it worthwhile to assess the effects of processing on the miRNA content in both milk and
dairy products.
Little is known about the effects of processing and storage on milk miRNAs levels.
In two studies, synthetic miRNAs were added to bovine milk and their stability after
exposure to harsh treatments such as acid and RNase was assessed and compared to the
stability of endogenous miRNAs in milk.6, 20 Synthetic miRNAs were rapidly degraded,
whereas endogenous miRNAs were resistant to treatment. However, the harsh treatments
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applied in these studies are not representative of the treatments applied in commercial
dairy production. In this study, we assessed the effects of pasteurization, fat content, cold
storage, heating as well as processing into dairy products on content of milk miRNAs.

MATERIALS AND METHODS
Chemicals. Guanidinium thiocyanate and ethanol were purchased for use in the
NucleoSpin miRNA plasma RNA extraction kit (Macherey-Nagel Inc., Bethlehem, PA).
TRIzol was purchased from Life Technologies (Grand Island, NY).
Milk and dairy products. Raw, whole, 2%, and skim cow’s (Bos taurus) milk was
obtained from The Pennsylvania State University Creamery (University Park, PA) from
separate collections in three consecutive weeks in May 2014. All milk was procured
from the Penn State Animal Science Department’s Holsteins breed herd. The milk for
this study was processed from using raw milk and cream routinely supplied to the Penn
State Berkey Creamery, University Park, PA and stored under intermittent agitation in a
22,712.5 liter raw milk silo at 2.2°C (Feldmeier Equipment, E-015-05; Little Falls, NY).
The milk contained 3.25% milk fat and 8.9% milk solids non-fat (near-infrared method,
CEM, Turbo Smart5, Model 907990; Matthews, NC).
For the preparation of the product, milk (3.25% Milk Fat; 12.15% Milk Solids Non Fat)
was pasteurized at 75.55°C with a 28-s holding time (APV Paraflow, Serial number
20053003000302; Goldsboro, NC). It was homogenized at 145 Bar and 60°C (APV
Gaulin Homogenizer, Serial Number 20052410702; Lake Mills, WI). The product was
standardized using a Westfalia Separator, type MSE 55-01-177; Oelde, Germany. A
details and process diagram for preparation of whole cow’s milk is presented in figure 1.
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After cooling the product was transferred to a 7200 liter refrigerated storage tank at 2.2°C
(Feldmeier Equipment, E-015-05; Little Falls, NY). The product was bottled on filling
machine (Federal Manufacturing, Serial Number 1/12.4GL843; Milwaukee, WI) and
stored in a conventional cold-milk warehouse at 3.0°C.
On our initial collection dates, milk of all fat levels were stored at 4ºC for up to 15 days, and
aliquots were taken and frozen at -80ºC every other day. In a separate experiment bovine cells

were removed from raw milk by centrifugation (500 g, 10 min, 4°C) to determine
whether somatic cells are a meaningful confounder when analyzing the concentrations of
miRNAs in milk from healthy cows. Samples were frozen at -80°C and shipped on dry
ice to Lincoln, NE, for miRNA analysis. Samples from all fat levels of milk on day 15
were heated in the microwave for 15 seconds and analyzed after cooling off to room
temperature. Dairy products other than milk were purchased from grocery stores in
Lincoln, NE. All samples were produced and analyzed as biological repeats in triplicate.
MiRNA analysis. Milk samples were spiked with a synthetic internal standard (twentyfive attomoles) prior to extraction of miRNAs using miSPIKE Synthetic RNA (IDT
Technologies).4 Dairy products (100 mg) other than milk were extracted using TRIzol
prior to addition of the synthetic internal standard. MiR-29b and miR-200c were
quantified using quantitative real-time PCR as described previously.4
Statistics. Analysis by Bartlett’s Test Homogeneity suggested that variances were
homogeneous.29 The paired t-test was used for pairwise comparisons. One-way analysis
of variance (ANOVA) and Fisher’s protected least significant differences were used
when comparing more than two groups. Repeated measures ANOVA was used for
assessing the effects of storage time on miRNA concentration. StatView 5.0.1 (SAS
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Institute; Cary, NC) was used for conducting statistical analyses. Means ± SD are
reported. Differences were considered statistically significant if P≤ 0.05.

RESULTS
Pasteurization and homogenization of raw milk resulted in a 63±28% decrease of
miR-200c in whole milk; effects were similar for 2% fat milk and skim milk (Fig. 3.1A).
The effect was less pronounced for miR-29b for which a significant decrease (67±18%)
was observed only in skim milk (Fig. 3.1B). Cold storage of milk did not affect the
concentration of mir-29b and miR-200c in whole milk, 2% milk and skim milk up to 15
days; 2% fat milk is shown as a representative example in Fig. 3.2. Somatic cells are not
meaningful confounds regarding the analysis of miRNAs in milk from healthy cows.
When somatic cells were removed from raw milk by centrifugation and analyzed for
miRNA content, the cellular miRNAs were found to contribute less than 2% of the total
miRNAs present in raw milk before centrifugation: 1.1±0.9% for miR-29b and
0.14±0.08% for miR-200c.
Processing in the household has the potential to cause a considerable loss of some
miRNAs in milk. For example, the concentration of miR-29b decreased by 40±28% when
processed milk was heated in the microwave and cooled to room temperature compared
to milk before heating (Fig. 3.3). In contrast, when milk was heated in the microwave the
concentration of miR-200c was not statistically different compared with unheated
controls.
The concentration of miRNAs varied considerably among the product tested (Table
3.1), but were generally lower than the concentration in pasteurized whole milk (compare
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to figure 3.2). Fresco queso dip was a notable exception and contained higher
concentrations of miRNAs than those observed in milk.

DISCUSSION
In a recent paper we reported the importance of milk miRNAs for gene regulation in
humans.4 That report has major implications for the roles of milk and possibly other dairy
products in human health. Cow’s milk contains meaningful quantities of 245 miRNAs,20,
30

and 71.4% of these miRNAs are predicted to target about 11,000 human transcripts

(unpublished observations). In addition to the roles of miR-29b and miR-200c in bone
health and cancer prevention,16-17, 24-25 respectively, miRNAs have been implicated in
various aspects of human health and disease including hypertension, insulin resistance
and diabetes, hyperlipidemia and atherosclerosis, reproduction, immune function and
Crohn’s disease.18, 20-21, 31-33
We propose that milk has a meaningful effect on human health, mediated by
miRNA-dependent gene regulation. The potential importance of dietary milk miRNA
intake is supported by data suggesting that 1) Americans consume large quantities of
milk and dairy products,28 2) a large proportion of milk miRNAs is encapsulated in
extracellular vesicles, thereby providing protection against degradation 5-6 and a pathway
for cellular uptake by endocytosis,34-35, and 3) milk miRNAs are resistant against
degradation during storage (this study).
The concentrations of miRNAs varied considerably among the dairy products tested
(Table 1), but were generally lower than the concentrations in pasteurized whole milk
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(compare Fig. 2). Fresco Queso Dip was a notable exception and contained higher
concentrations of miRNAs than those observed in milk.
Our previous studies of milk miRNAs in humans and mice were conducted using 1%
fat milk from the grocery store.4 Based on this study, the content of miRNAs is about two
times higher in unprocessed milk compared with pasteurized, store-bought milk. Note
that we have no intent recommending the consumption of raw cow’s milk by humans,
because of food safety concerns associated with raw milk. We observed that a loss of
milk miRNAs occurred only during pasteurization, homogenization, and processing to
dairy products. This observation is consistent with previous studies of milk miRNAs. For
example, endogenous miRNAs were not degraded when milk was exposed to harsh
treatments such as low pH or treatment with RNase.6, 20 It is reasonable to propose that
encapsulation of miRNAs in extracellular vesicles5 prevents miRNA degradation, based
on the following lines of evidence. 1) When synthetic miRNAs are added to milk and
subjected to low pH or RNase treatment, the miRNAs are rapidly degraded.6, 20 2) When
exosome membranes in milk were disrupted by sonication for preparing miRNA-depleted
mouse diets in previous studies, miR-29b was rapidly degraded to concentrations below
detection limit.4 Presumably, degradation was due to milk RNases gaining access to
miRNAs released from exosomes. 3) When milk was fermented to produce yoghurt,
miRNA concentrations decreased to levels much lower than in milk (this study). We
speculate that the decrease was due to the lysis of exosomes during fermentation and the
large amounts of RNases produced by microbes. 4) When milk was homogenized,
miRNA concentrations decreased by on average 50% (this study). We speculate that the
decrease was caused by a disruption of exosome mebranes by shear forces applied during
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homogenization. Collectively, our studies suggest that milk, and perhaps dairy products,
have the potential to contribute to the miRNA body pool in humans.
Some uncertainties remain to be addressed in future studies. For example, this study
was modeled based on miR-29b and miR-200c, however, there is a possibility that
distinct miRNAs may be differentially metabolized.8, 36 Another layer of uncertainty is
the possible effects of feeding regimens, season, and breed on the miRNA content in
milk. Moreover, while this study suggests that somatic cells in milk from healthy cows do
not contribute meaningful amounts to the total miRNA content in milk, it is possible that
the increased somatic cell count in milk from cows suffering from mastitis37 may cause
an artificial increase in milk miRNA concentrations. Our previous studies suggest that
plasma miRNA concentrations decrease by 61% in mice fed a milk miRNA-depleted diet
for four weeks. This observation is consistent with milk miRNAs contributing
meaningful quantities to the miRNA body pool, but does not necessarily establish the
essentiality of dietary miRNA intake. Clearly, this is an uncertainty that will need to be
addressed in future studies. Finally, it is conceivable that miRNAs from foods other than
milk also contribute toward the total body pool of miRNAs.
ABBREVIATIONS USED
miR, microRNA; miRNA, microRNA
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Figure 3.1. Loss of miR-200c (A) and miR-29b (B) during milk pasteurization and
homogenization of milk with different fat content. a,bSignificantly different (n=3
biological replicates, P<0.05).
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Table 3.1. Concentration of miRNAs-29b and -200c in dairy products
MiRNA
_______________
Product

miR-29b

______________
miR-

200c
fmol/kg
Best Choice Yogurt

0.9±0.10

37.6±2.8

Fresco Queso Dip

36.1±5.5

1029.8±478.6

Greek Yogurt

14.2±3.9

462.3±126.9

Half and Half

3.0±0.17

513.3±159.2

Heavy Whip Cream

2.6±1.3

342.0±132.9

Parmesan Cheese

4.9±1.9

232.0±64.5
Upstate Farm Yogurt
Data are means±SD, n=3.

2.4±1.0

216.9±93.8
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Chapter 4
Future Study
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Although there is still a debate whether miRNA can be transferred across species
(1-3), our lab has provided an evidence that miRNA indeed can be transported across
species (4, 5). It is hypothesized that the miRNA transport across species was mediated
by exosomes or other extracellular vesicles as these small vesicles protect the miRNA
from enzymatic degradation and harsh environment such as low pH (6, 7). Furthermore,
exosomes also facilitated the transport into the recipient cells as numerous studies have
reported the ability of the cells to internalize exosomes and use the miRNA cargo inside
exosomes to promote function (5, 8-12).
In recent study, we provide another evidence that cow’s milk exosomes can be
transported into human endothelial cells through endocytosis process. However, several
endocytosis pathway warrant further study. For instance, we only provide the evidence
that the transport was mediated by actin-dependent process. Actin is required for most
endocytosis process including phagocytosis, macropinocytosis and chlatrin-mediated
endocytosis (13-15). This indicated the non-specific endocytosis mechanism that
mediated the uptake of cow’s milk exosomes into human endothelial cells. Therefore, it
is necessary to address this issue by performing another inhibitory studies or protein
inhibition through RNA interference, specific for each endocytosis mechanism, to answer
specific endocytosis-mechanism.
Study suggest that surface glycoprotein in exosomes play an important role in
cellular recognition and internalization of exosomes by target cells (16-18). In this study
we suggest that glycoprotein surface in cow’s milk exosomes is important for mediating
the uptake into human endothelial cells as indicated by lower uptake of cow’s milk
exosomes in the presence of galactose and when the milk exosomes was treated with
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proteinase K. It is interesting if we could provide the glycoprotein class or component in
surface area of cow’s milk exosomes that mediated the uptake process in human
endothelial cells. Thus, performing another transport study using surface-blunt
glycoprotein of milk exosome is important in the future to characterize the glycoproteins
that mediates the uptake in human cell. Additional mass-spectrophotometry (MS) to
identify the surface glycoprotein in cow’s milk exosome can also be used to support the
data derived from the transport study using surface-blunt glycoprotein of cow’s milk
exosomes.
In addition, we only based our experiment by indirect observations. It is still not
clear whether the exosomes from cow’s milk is indeed internalized by endocytosis, not
by fusion with plasma membrane. Electron microscopy image or phase contrast
microscopy should be performed in the future study to clarify the data obtained by the
FM4-64 labelled exosomes.
Recent study suggests that cow’s milk exosome can be transported across the rat’s
intestinal cells without being degraded or repackaged by the intestinal cells (19).
However, question remains whether this event occur in human peripheral cells and the
miRNAs present in cow’s milk exosomes can promote function after being transported
across endothelial cells. Transwell study is a way to answer this question. In the first
experiment, HUVEC were grown in the apical surface and cow’s milk exosomes were
added when HUVECs have formed monolayer in the apical surface. Exosomes was
isolated from the apical and basolateral surfaces of transwell by using differential
centrifugation method. Electron microscopy, western blot and Q-RT-PCR for selected
miRNAs were performed to characterize the exosomes isolated from both of the surfaces.
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In the second experiment, HUVECs were grown in the apical surface of transwell and
stable transfected HEK-293 carrying the miR-200c reporting gene were grown in the
basolateral of transwell. Milk exosomes was added and luciferase activity was measured
after incubation for several hours.
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qRT-PCR primers used to quantify gene expression

microRNA Forward Primer Sequence (5-3’)

Reverse Primer Sequence (3-5’)

miSpike

CTCAGGATGGCGGAGCGGTCT

Universal primer mix

miR-29b

GTAGCACCATTTGAATCAGTGTT

Universal primer mix

miR-200c

TAATACTGCCGGGTAATGATGGA

Universal primer mix

